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ABSTRACT
Dietary polyphenols such as apigenin are the secondary plant metabolites reported to
reduce incidence of many chronic diseases including cancers and chronic inflammation.
However, the high hydrophobicity of lipophilic polyphenols results in low water solubility and
bioavailability, which limits the therapeutic efficacy and impedes further applications in
aqueous food systems. Nanoencapsulation is a potential approach to address the above
problems. Thus, the objective of this dissertation was to develop nanodelivery systems of
apigenin utilizing dairy proteins as carriers, followed by evaluating the in vitro and in vivo
anticancer efficacy and anti-inflammatory effects. The first delivery system was fabricated by
increasing mixtures with 0.6-2.0 mg/mL apigenin and 1% w/v whey protein isolate (WPI) to
pH 13, followed by neutralization (the pH-cycle). The encapsulation efficiency was 93.4498.38% and the loading capacity was 57.19-195.78 mg-apigenin/g-WPI. Nanodispersions
maintained stable hydrodynamic diameters of 180-240 nm during 30-day ambient storage.
Nanoencapsulation enhanced the cellular uptake of apigenin in human HCT-116 and HT-29
colorectal cancer cells, and the oral bioavailability in C57BL/6J mice. In vivo anti-colorectal
cancer efficacy was evaluated in ApcMin+ mice. Results showed that neither free apigenin nor
encapsulated apigenin positively suppressed colon carcinogenesis, by insignificantly affecting
polyps numbers, tissue apoptosis, tumor marker expressions (COX-2，β-catenin, cyclin D1,
and c-myc), and levels of inflammatory cytokines (TNF-α, IL-6, and IL-1β). The second
nanodelivery system was fabricated by co-encapsulating apigenin and curcumin at various
mass ratios in sodium caseinate using the pH cycle method. Curcumin enhanced the
iv

encapsulation efficiency and dispersion stability. When evaluated for anti-inflammatory
activities in LPS-induced RAW 264.7 macrophages under non-toxic concentrations,
unencapsulated polyphenol mixtures with an increased proportion of curcumin showed
synergistic anti-inflammatory activities, evidenced by a combination index of smaller than 1,
in inhibiting nitric oxide production, suppressing iNOS enzyme expression, decreasing proinflammatory cytokines (TNF-α and IL-6), and reducing ROS production. These synergistic
anti-inflammatory effects of apigenin and curcumin were enhanced after coencapsulation.
Findings from the present dissertation may provide insights to develop functional foods
incorporated with lipophilic phytochemicals as potential strategies for disease prevention.

Keywords: apigenin, dairy proteins, nanoencapsulation, pH-cycle, bioavailability, anticancer,
anti-inflammatory, synergistic interactions
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Chapter 1. Introduction
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1.1 Colon cancer
1.1.1 Incidence and mortality
Cancer, a malignant neoplasm caused by the abnormal proliferation and differentiation of
cells, continues to threat human life as the second leading cause of death globally, only
exceeded by heart disease.1-4 There were 18.1 million new cases and 9.6 million deaths from
cancer worldwide estimated in 2018.5 The global burden of cancer is predicted to reach 21.7
million newly diagnosed cases and 13 million mortalities by 2030.6
According to the Global cancer statistics, colorectal cancer (CRC) has been ranked the
third most commonly diagnosed cancer, accounting for 10.2% of all incident cancers.5 In 2018,
over 881,000 deaths were estimated among the total 1.8 million new CRC cases, i.e., about 1
death in 2 CRC cases, which made it the second most prevailing cause of cancer-related death
in the overall population.5 In the past two decades, there has been a decline in the incidence
and mortality rates in the adults aged 50 years and over, which is largely attributable to the
screening to prevention and early detection.7. However, the number of new cases is rising
among young adults aged 20-49 years.5, 8, 9 It is projected that the global population has to bare
a 22% increase of the CRC worldwide burden to more than 2.2 million new cases and 1.1
million cancer deaths by 2030.10
1.1.2 Development of colon cancer
Colon carcinogenesis is a complex multistage process conventionally defined as three
major phases: initiation, promotion and progression.4, 11, 12 Along these steps, CRC develops as
a consequence of the progressive accumulation of genetic mutations and epigenetic alterations
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that cause conversion and progression of normal functioning colonic epithelium mucosa to
adenoma and, eventually, carcinoma.13-15
This “adenoma-carcinoma sequence” is resulted from series activation of oncogenes and
inactivation of tumor suppressor genes.14 One of the critical events in colorectal tumorigenesis
is the aberrant activation of β-catenin, which is an important cancer target that vitally involved
in both cell adhesion and intracellular signaling.14-16 β-catenin cooperates with adenomatous
polyposis coli (APC), a tumor suppressor gene, forming a complex, which is degraded by the
ubiquitination process under normal circumstances.17 However, mutations in APC genes cause
the incapability to bind with β-catenin, resulting in a larger amount of β-catenin in the cytosol,
which subsequently translocates into the nucleus and finally promotes cells proliferation.18-20
Thus, APC inactivation along with the aberrant activation of β-catenin are key initial events in
the tumorigenic process, resulting in the transition of preneoplastic cells to aberrant crypt foci
(ACF) and toward development of adenoma or polyps, which always start out as benign.21-23
Further progression of such early-stage adenomas to carcinoma in situ and invasive metastatic
carcinoma requires several additional pathways, involving mutational activation of oncogenes
such as Kirsten rat sarcoma viral oncogene homolog (K-ras) and proto-oncogene B-Raf, as
well as inactivation of tumor suppressors including Transforming growth factor beta receptor
II (TGFβR2), p53 and the proapoptotic protein Bax.2,

24-29

Cyclooxygenase 2 (COX-2)

expression is also increased in the transition of benign adenoma to malignant
adenocarcinoma.30-32
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1.1.3 Risk factors of colon cancer
A number of risk factors are associated with the development of colon cancer, including
inherited genetic factors, lifestyle and environmental factors.33 Hereditary non-polyposis
colorectal cancer (HNPCC or Lynch syndrome), which is induced by mutations in the DNA
mismatch repair system, and familial adenomatous polyposis (FAP) that results from the
germline mutation in the tumor suppressor APC gene, make up the two main forms of inherited
colon cancers.34-36 However, only approximately 5% of CRC patients are diagnosed to have
such inherited genetic predisposition. Sporadic CRC, on the other hand, accounts for the
majority of cases.33, 37
Incidence of CRC varies greatly over the world, with a higher rate found in parts of Europe,
New Zealand, Australia and North America, while the occurrence in most regions of Africa and
South Asia remains relatively low.5, 33 In addition, rates are elevated due in part to economic
development and the adoption of a western lifestyle. Japan provides a striking example of an
Asian country where CRC is traditionally uncommon.38 The booming prosperity and the
dramatically shifted dietary pattern with sharply increased intake of meat and fat have been
met with the remarkable concomitant growth in both prevalence and mortality of colon cancer
since the middle of the twentieth century.39, 40 Such changes clearly suggest that occurrence of
colon cancer is highly positively associated with the poor environmental and lifestyle factors
such as unhealthy diet, smoking, alcohol abuse, as well as lack of physical exercise.1, 41, 42
Epidemiological studies indicate that dietary factors are significantly involved in the
occurrence of CRC, which are estimated to be responsible for 30% to 50% of CRC

4

worldwide.32 A high intake of red and processed meat, refined cereals and starches, saturated
and trans-fatty acids, and sugars have been correlated to the augment rate of CRC incidence,
while diets rich in fruits, vegetables, fibers, fish, unsaturated fats and whole grains are likely to
lower CRC risk.43-45 Nutritional recommendations from the World Cancer Research Fund
(WCRF) and the American Institute for Cancer Research (AICR) suggest the importance of
increased consumption of vegetables and fruits, to help reduce the potential of cancer
development and progression.46 A meta-analysis concluded that high intake of fruits and
vegetables were found to decrease 13% and 40% lower CRC risk, respectively.44 The protective
effects of fruits and vegetables may be largely attributable to the abundant bioactive ingredients
consist in them, which have beneficial health activities. In addition, consumption of alcohol
has implications in CRC development due to the mutagenic and pro-carcinogenic activities of
acetaldehyde metabolized from alcohol.47 Besides, tobacco makes contributions to
approximately 20% of CRCs, as more than 7000 dangerous components containing various
carcinogens exist in tobacco smoke.48, 49
Apart from these, age, sex and race are also the factors that affect CRC risk. While the
probability of developing colon cancer augments significantly over 50 years of age,50 men have
two times higher risk than women.51 Besides, African American populations are more prone
than Caucasian populations to develop colon cancer, while incidence of CRC is lower in Asian
Americans.35 Individuals with some diseases including obesity, type 2 diabetes and
inflammatory bowel disease (IBD) like ulcerative colitis or Crohn’s disease are also at
considerably greater risks for developing colon cancer.52, 53
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1.1.4 Current therapeutic approaches and challenges
CRC is a highly complex cancer resulted from a various genetic mutations and epigenetic
alterations, which leaves great challenges to combat this calamity. Current therapeutic
treatments of CRC involve a combination of surgery, radiation, and chemotherapy based on the
different diagnosed stages.54 Surgical resection remains curative when it is feasible. However,
only 70% of colorectal tumors are resectable and CRC is in high probability of relapse, which
drives the importance of the adjuvant chemotherapy.55 Drug discovery endeavors have yielded
a wide array of chemotherapeutic agents such as oxaliplatin (OX), irinotecan (IT), 5Fluorouracil (5-FU) and so forth.56-59 Main mechanisms for chemoprevention are to suppress
the uncontrolled cell proliferation, induce cell apoptosis or autophagy, regulate cell cycle,
inhibit tumor cell migration and invasion, and simultaneously stimulate immune response of
patients.54, 60
Despite significant advancements in adjuvant therapies of CRC treatment, approximately
one half of patients will suffer local recurrence or distant metastasis during the process of the
illness.61 The 5-year survival success rate for patients with advanced CRC, additionally,
remains less than 10% as ever.62 The gradually developing resistance of colon tumor cells to
the majority chemotherapy drugs largely accounts for these depressing facts. For instance, the
treatment response rates of 5-FU in the advanced CRC yielded only 10-15%, which limited its
usage.58 Resistance to oxaliplatin is evidenced to associate with the reduced ability to induce
mitochondrial-mediated apoptosis.63 Combinational chemotherapy is used to eliminate the
ineffectiveness due to resistance, which is targeting multiple molecular pathways to induce cell
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death.56,

64

Nevertheless, cancer cells still develop resistance in later rounds of therapy,

especially when it tends to relapse and metastasize.54 In addition, existing chemotherapeutic
drugs are not selective enough, and are mostly cytotoxic and not only work on cancer cells, but
also affect normal but fast-dividing cells such as hair follicles and epithelial cells in the
digestive system,65 which lead to severe adverse side effects, including gastrointestinal
complications, alopecia, bone marrow suppression, acute and chronic neuropathy, and
hypersensitivity reactions.66, 67 As such, alternative chemopreventive agents that are able to
target multiple hallmarks of cancer meanwhile exhibit limited toxicity are urgently needed.
1.2 Chronic inflammation
1.2.1 Inflammatory response
Inflammation is characterized as a defensive response of the immune system against
various biological, chemical, or physical stimuli, such as pathogens (e.g. bacteria and viruses),
trauma (wounds or burns), detrimental chemicals, as well as allergic or auto-immune reactions,
which causes a disruption of tissue homeostasis.68-70
Depending on the type of stimulus and the efficiency to remove such stimulus,
inflammation can be typically acute or chronic.71, 72 Acute inflammation is an innate and initial
response that occurs within minutes following infections or tissue injuries. It is a short-term
process, lasting few hours or several days, in which fluid and plasma proteins exudate and
leukocytes (mostly neutrophils) emigrate from blood to the extravascular damaged tissues to
eliminate the agents that could potentially cause tissue injury and restore homeostasis to the
affected tissue.71, 73-75 These processes are always along with increased temperature in local
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tissues, redness, swelling, pain, and loss of tissue function.74, 76 However, acute inflammation
is a self-limited beneficial response and disappears when immune system successfully removes
damaging stimulus and the homeostatic state recovers.77 In contrast, failure to clear such
detrimental sources will cause a chronic phase of inflammation.
Chronic inflammation is an extended inflammation period, persisting for weeks, months
or even years. Upon an immunogenic stimulus, inflammatory responses are initiated through
the identification of exogenous pathogen-associated molecular patterns (PAMPs) or damageassociated molecular patterns (DAMPs) by pathogen-recognition receptors (PRRs).78-82 Some
of the extensively studied PRRs belong to the toll-like receptors (TLRs) family which are
membrane receptors on macrophages, dendritic cells and so on, playing a major role in the
immune system.83 During inflammation, immune cells such as macrophages and lymphocytes
are firstly activated by recognizing PAMPs and DAMPs with TLRs. Activated TLRs recruit
several adapter proteins within the cytosol such as MyD88, TRIF, TRAF, and IRAK. Binding
of TLRs with adapter proteins stimulates inflammatory responses and sequentially induces
signaling cascades involving with intracellular inflammatory signaling molecules, and
ultimately activates inflammatory signaling pathways including nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB), interferon regulatory factor (IRF), and activator
protein-1 (AP-1) pathways.84-86 Various pro-inflammatory mediators are activated in
inflammatory signaling pathways, such as nitric oxide (NO), prostaglandin E2 (PGE2), tumor
necrosis factor-alpha (TNF-α), interleukins (IL-1β and IL-6), and pro-inflammatory enzymes,
including inducible nitric oxide synthase (iNOS) and cyclooxygenases (COX-2) are
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expressed.71,

87, 88

Excessive amount of inflammatory mediators may be resulted from the

chronic inflammation, which may promote the occurrence of various chronic diseases.89, 90
Increasing studies indicate that inflammation in its chronic phase has been widely associated
with the development of numerous chronic diseases such as asthma, rheumatoid arthritis,
inflammatory bowel diseases, atherosclerosis, obesity, diabetes and various cancers.89, 91-96
1.2.2 Chronic inflammation and cancer development
It is well documented that chronic inflammation acts as key risk factors on the initiation
and progression of several diseases especially cancers.97-99 Over 15% of cancer malignancies
are initiated by inflammation.100 For instance, almost 15-20% of smokers with bronchitis are
susceptible to develop lung cancer during their lifetime.101 Chronic form of gastritis, an
inflammation of stomach lining that is induced by the infection of Helicobacter pylori has been
shown to lead to gastric cancer.102, 103 Besides, one well established link between chronic
inflammation and human cancer is that inflammatory bowel disease (such as ulcerative colitis)
serves as a precursor to colon cancer.104, 105
Mechanisms contributing to the oncogenic roles of chronic inflammation have been
proposed by a large body of epidemiological studies, including induction of genomic instability,
alteration of the genomic epigenetic status, enhancement of cell growth, inhibition of cell
apoptosis, provocation of angiogenesis, and promotion of tumor cells invasion and
metastasis.102,

106

Tumor progression are correlated to the increased production of various

markers, including transcription factors such as NF-κB, AP-1, and signal transducer and
activator of transcription 3 (STAT3), pro-inflammatory mediators including cytokines,
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chemokines, 5-lipoxygenase (5-LOX), COX-2, matrix metalloproteinases (MMPs), hypoxiainducible factor 1α (HIF-α), and reactive oxygen species.90,

107

Therefore, suppressing

inflammatory molecules and thus controlling chronic inflammation has been regarded as a
potential strategy for the prevention and treatment of cancers.
1.2.3 Oxidative stress and chronic inflammation
Reactive oxygen species (ROS) are free oxygen or nitrogen radicals that are formed as
natural byproducts of normal metabolism of oxygen through cellular mitochondrial respiratory
system,71 including superoxide anion (O2-), hydrogen peroxide (H2O2), hydroxyl radical (HO•),
and nitric oxide (NO•).108 In normal metabolic conditions, such oxidants functions in the
germicidal effect of phagocytic cells and are eliminated by the biological protective antioxidant
system involving several antioxidant enzymes and biomolecules.109 However, persistent and
long term immune responses, or over exposure to various stimuli such as xenobiotics,
pollutants, smoke, drugs, toxic chemicals, and heavy metal ions, result in excessive ROS
production.110 The abnormal and elevated level of ROS yields an imbalance between oxidants
and antioxidant defense system, leading to detrimental effects, which is termed as oxidative
stress.111 Overproduction of ROS stimulates immune cells to release a variety of mediators,
which provokes recruitment of additional macrophages into the inflammatory site.112 In
addition, owing to the presence of an unpaired electron in the outermost shell of electrons, ROS
are highly reactive, attacking and damaging vital biomolecules, such as intracellular proteins
or enzymes, membrane lipids, carbohydrates, and nuclear DNA in cells and tissues, thereby
causing undesirable protein modification, lipid peroxidation, DNA fragmentation and then cell
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death.113, 114 Therefore, the persistent recruitment of inflammatory cells, repeated stimulation
of pro-inflammatory mediators and ROS generation, and continued proliferation of
genomically unstable cells are believed to participate in the etiology of several chronic diseases,
such as inflammation and cancers.115, 116
1.2.4 Inflammatory mediators
Inflammation involves a set of complex chemical signals responding to traumatic,
infectious, toxic and allergic agents and is modulated by immune cells.70 A number of
mediators, including cytokines, chemokines, pro-inflammatory transcription factors, and proinflammatory enzymes molecularly participate in this process117
1.2.4.1 Cytokines
Cytokines, proteins that mediate cell-to-cell communications, are believed to at least
partially control the systemic immune response.73 They are mainly produced by activated
lymphocytes and macrophages as well as endothelial and epithelial cells and are capable of
regulating diverse physiological processes, including cell growth, differentiation, migration,
and immune response.73, 118 Cytokines have pleiotropic functions that not only can modulate
an antitumoral response, but also can induce cell transformation and malignancy during chronic
inflammation.70 Thus, they can be broadly classified as pro-inflammatory cytokines such as IL1, IL-2, IL-6, IL-1β, and IFN-γ, and anti-inflammatory ones like IL-4, IL-10, and TGF-β.118, 119
Among them, TNF-α and IL-6 are two widely studied cytokines, playing predominant roles in
the inflammatory process and the downstream chronic inflammation-related diseases.75, 120
Specifically, tumor necrosis factor-alpha (TNF-α) is a potent pro-inflammatory cytokine
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that exhibits various biological activities by binding to general receptors on the surface of target
cells.121 TNF-α promotes various chemokines and cytokines to commence acute and chronic
phases of inflammation and is implicated in the development of carcinogenesis.122, 123 It can
induce DNA damage, facilitate angiogenesis, and provoke COX-2 expression to initiate and
promote tumor growth.105 Various human cancer cells, such as those of breast, prostate,
colorectal, and bladder have been detected in an overexpression of TNF-α.124-127 Interestingly,
studies have shown a dual role of TNF-α in carcinogenesis. A high level of TNF-α was found
to be able to both causes necrosis and promote tumor cells growth.118 Pleiotropic functions of
TNF-α, with both pro-inflammatory and immune-regulatory activities, were also demonstrated
during chronic inflammation.128
Interleukin (IL)-6 is another vital pro-inflammatory cytokine playing a key role in the
acute response associated with the stimulation of acute phase proteins synthesis by liver.75, 121
IL-6 instructs the transition from acute to chronic inflammation in combination with its soluble
receptor sIL-6Rα, by alternating the structure of leucocyte infiltration from polymorphonuclear
neutrophils to monocyte/macrophages.75 As such, IL-6 is known to favor chronic inflammation
and related diseases. For instance, elevated serum level of IL-6 has been implicated in
rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and some systemic cancers.129132

Besides, it has been demonstrated that IL-6 modulates genes expressions that involved in

cell cycle progression and suppression of apoptosis, mainly through the JAK (Janus kinase)STAT signaling pathway.118 Thus, IL-6 has been turned into a potential drug target in the
treatment of chronic inflammatory diseases.
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1.2.4.2 Nitric oxide (NO) and inducible nitric oxide synthase (iNOS)
Nitric oxide (NO), a gaseous free radical, is another important inflammatory mediator
linking chronic inflammation and a variety of chronic diseases.118 The production of NO results
from converting L-arginine into NO and L-citrulline by nitric oxide synthase (NOS), involving
endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS).133,

134

NO

produced by constitutively expressed eNOS and nNOS at low physiological levels is essential
to maintain immune homeostasis,135 whereas prolonged larger amounts of NO are synthesized
by iNOS, which is a dimeric and Ca2+ independent enzyme, highly expressed by inflammatory
stimuli.136 As a reactive radical, excessive production of NO causes DNA damage by impairing
the functionality of cellular machinery that is responsible for DNA repair.137 Overproduction
of NO also induces p53 gene mutations,138 thereby inducing genomic instability.139
On the other hand, iNOS is not detectable in healthy tissues but is highly expressed in
response to continuous stimulation, including lipopolysaccharide (LPS) and pro-inflammatory
cytokines, which in turn can increase the production of NO.136, 140 It has been reported that
improper up-regulation of iNOS and NO is involved in the pathophysiology of diverse
malignant tumors, such as breast, colorectal, lung, prostate cancers, and melanoma.138, 141, 142
1.2.4.3 Cyclooxygenase-2 (COX-2)
In addition to iNOS, cyclooxygenase-2 (COX-2) is another pro-inflammatory enzyme
involved in the inflammatory process, which converts arachidonic acid (AA) into
prostaglandins.76, 117, 143 There are two prostaglandin H synthase isoforms, COX-1 and COX-2.
While the expression of COX-1 exists in many tissues, mitogens, tumor promoters, and growth
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factors regulate the expression of COX-2 that can also be stimulated by pro-inflammatory
cytokines and oncogenes.76, 139 Aberrant induction of COX-2 has been implicated in several
types of cancers, by up-regulating generation of prostaglandins, which promote cell survival,
angiogenesis, and metastasis.16, 144-146 It is frequent to found elevated levels of COX-2 in
numerous human malignancies, such as breast, gastric and colon tumors, suggesting a role of
COX-2 as a regulator between inflammation and cancers.147 For instance, overexpression of
COX-2 has been detected in up to 90% of colon carcinomas and 40% of colon adenomas.139
Thus, COX-2 is vital target for anti-inflammation remedy as well.
1.2.5 Current treatments for inflammation
Based on the World Health Organization (WHO) report, chronic inflammation has been
the greatest threat to public health, as three of every five individuals die from chronic
inflammation induced diseases like diabetes, heart disorders, and cancers.148 It is anticipated
that the prevalence of such diseases will rise steadily in the next 30 years.148 In this respect,
effectively treating chronic inflammation is of primary importance.
Currently, aspirin and other non-steroidal anti-inflammatory drugs (NSAIDAs) are
commonly applied to combat inflammation.76 However, these NSAIDAs are non-selectively
and irreversibly inhibit the activity of both COX-1 and COX-2, whereas constitutively
expressed COX-1 is essential for homeostatic functions.149, 150 Due to the unexpected COX-1
inhibition, long-term administration of NSAIDs results in severe adverse effects, especially
gastric ulceration, due to the protective effects of COX-1 for the stomach lining.71, 76 In addition
to gastrointestinal disturbances, NSAIDs also can cause salt and water retention, renal
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dysfunction, bronchospasm, and hypersensitivity reactions.71 Compare to non-selective
NSAIDs, COX-2 selective inhibitors (known as Coxibs) such as celecoxib and rofecoxib, have
the established efficacy in the treatment of inflammation with better gastrointestinal safety.71
Nevertheless, Coxibs can promote renal sodium reabsorption, thus predisposing to
hypertension and edema, which is related to cardiovascular complications.151,

152

In

consequence, there is still a pressing need to develop safer, less toxic and more cost-effective
therapeutic alternatives.

1.3 Dietary polyphenols
1.3.1 Classification and chemical structures of polyphenols
As noted, poor diet habits have been evidenced to further increase the cancer burden, and
researchers therefore have turned to dietary factors to intervene and prevent cancers. A great
deal of studies have associated the increased consumption of fruits and vegetables with the
reduced cancer incidence. Possible mechanisms accounting for the protective effects of such
natural foods are largely ascribed to the abundant bioactive compounds existing in them, such
as polyphenols, which possess health beneficial effects.
Dietary polyphenols are naturally-occurring secondary plant metabolites that are formed
to protect plants against environmental stressors and stimulators such as reactive oxygen
species and photosynthetic stress.153, 154 They are characterized by the presence of at least two
phenolic groups in the structure and are ubiquitous in diverse fruits, vegetables, nuts, seeds,
legumes, and plants.155, 156 Over thousands of polyphenols have been identified, ranging from
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low molecular weight phenolic acids to the large and highly polymerized tannins.156,

157

Polyphenols are differentiate from different numbers of phenolic rings and the way they bond,
and are broadly divided into four common classes, including phenolic acids (such as caffeic
acid and ferulic acid), flavonoids, lignans and less common stilbenes (e.g. resveratrol).158, 159
Among these, flavonoids are the most widely studied group, which can be further grouped
into several sub-classes. Flavones include luteolin and apigenin; flavonols include mostly
quercetin, myricetin, and kaempferol; flavan-3-ols include the class of catechins; anthocyanins
mainly include malvidin, cyanidin, delphinidin, and pelargonidin; and isoflavones include
genistein and daidzein.160-162 Flavonoids share the same structural skeleton, a 15-carbon
phenylchromone structure (C6-C3-C6) composed of two benzene rings (A and B) linked via a
heterocyclic pyrane C ring.163 Modification to the structure skeleton, via different levels of
oxidation and substitutions to the C ring, makes contribution to diverse types of flavonoids,
and their versatile biological functions.
1.3.2 Pharmacological properties of polyphenols
Proverbially, natural phenolic compounds are believed to confer a broad spectrum of
pharmacological activities, such as antioxidant, anti-inflammatory, anti-carcinogenic, anti-viral,
anti-bacterial and anti-atherogenic activities.164, 165 Numerous studies have contributed to this
postulation.
1.3.2.1 Polyphenols and colon cancer
There is a strong epidemiological evidence suggesting that consumption of diets high in
fruits, vegetables and plant foods is associated with the decreased risks of diverse cancers,
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especially reduced the prevalence of colorectal cancer, which appears to be the most relevant
to dietary factors.44,

166

Therapeutic effects of numerous polyphenols such as curcumin,

resveratrol, quercetin, and green tea catechins on combating versatile cancers have been well
documented.154,

167, 168

Curcumin has been recognized as a promising antitumor drug via

inhibiting tumor initiation, promotion, invasion, and metastasis through a variety of
mechanisms.169-173 Resveratrol has been reported to significantly reduced β-catenin, a key
component of the Wnt signalling pathway in colon cancer regulation.174 In vitro experiments
showed that proanthocyandins effectively inhibited the PI3k/PKB pathway and induced
apoptosis in colon cancer cells.175 Lycopene was also found to inhibit the proliferation of
human colon cancer cells HT-29 via inhibition of the Akt signaling pathway.176
1.3.2.2 Polyphenols and chronic inflammation
As chronic inflammation is intimately associated with the progression of various cancers,
mounting epidemiological studies have reported the role of polyphenols in the remedy of
inflammation. Oxidative damage to biomolecules such as proteins, lipids and DNA is supposed
to be closely linked to human health concerns, including chronic inflammation and the
downstream related chronic diseases such as carcinogenesis, neurodegenerative disorders and
cardiovascular diseases.71, 177 In this regard, neutralizing the over generated free radicals such
as ROS by supplemental antioxidants is a promising approach to attenuate inflammation.
Polyphenols are the most frequent antioxidants in human diets.157,

178

The acceptance an

electron by the phenolic groups of polyphenols to form relatively stable phenoxyl radicals
results in the disruption of oxidation chain reactions in cellular components.179
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Apart from anti-oxidative activity, polyphenols perturb the inflammatory response by
mediating various inflammatory factors, including cytokines, pro-inflammatory enzymes and
also transcription factors.180, 181 Green tea catechins was reported to down-regulate COX-2
expression in LPS-induced macrophages and inhibit IL-1β dependent pro-inflammatory signal
transduction in cultured respiratory epithelial cells182, 183. Using LPS activated macrophages,
quercetin was found to inhibit the iNOS expression, which subsequently resulted in suppression
of NO generation.184 Besides, inhibition of NF-κB may account for the anti-inflammatory
effects of many polyphenols including resveratrol, 6-gingerol, and caffeic acid phenethyl ester
(CAPE).76
1.3.3 Challenges of applying polyphenols for disease intervention
In spite of the wide spectrum of pharmacological effects, the further use of dietary
polyphenols in the pharmaceutical field is impeded due to some physiological limitations, such
as the poor aqueous solubility, low stability, and the resultant poor bioavailability.
1.3.3.1 Solubility and stability
Chemically, dietary polyphenols have phenyl rings and phenolic groups in the structure.
Due to these structural characteristics, many dietary polyphenols are lipophilic, thus resulting
in a low solubility in aqueous environments. For instance, curcumin is only sparingly soluble
in water, with the solubility of only about 11 ng/mL,185 while it has a high solubility in organic
solvents such as dimethyl sulfoxide, acetone and ethanol.186 Similarly, resveratrol has a water
solubility of less than 0.05 mg/mL, which consequentially leads to an undesired oral
bioavailability.187
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In addition, the structural characteristics of polyphenols are responsible for the
susceptibility to degradation by various environmental factors, such as pH, ionic strength,
temperature, oxygen and light,188 which results in considerable changes in their
physicochemical and functional properties.189 Typical reactions leading to chemical
degradation of bioactives include oxidation, reduction, hydrolysis, and isomerization.190 In
regard to curcumin, the lipophilic molecule with phenolic groups and conjugated double bonds,
is degraded rapidly by light and basic pH, while only less than 20% of total curcumin
decomposed at 1h under acidic conditions.191, 192
1.3.3.2 Bioavailability
The therapeutic efficacy of phenolic compounds depends primarily upon their
bioavailability. Bioavailability is defined as the rate and extent to which the bioactive
ingredient is absorbed into systemic circulation and becomes available at the targeted site.193 It
relies on the forms of the bioactive compounds that present in vivo, the relative absorption from
the intestine, and also the rate of metabolism and clearance from the body.194 Many lipophilic
phenolic components have low bioavailability within the human gastrointestinal tract, which
may result from the low bioaccessibility, poor absorption, high rate of metabolism or rapid
elimination, as well as their poor solubility, high melting point, and chemical instability.195, 196
As an example, most of the ingested EGCG is not absorbed and is there metabolized by the gut
microbiota; the bioavailability and thus potential bioactivity can be low.197 Therefore,
enhancing the bioavailability of dietary polyphenols is critical to enable the health effects in
vivo.
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1.3.4 Apigenin
1.3.4.1 Role of apigenin in colon cancer
Apigenin (4’,5,7-trihydroxyflavone) (Figure 1-1), one of the most promising polyphenols,
is predominantly distributed in several fruits, vegetables, and medicinal plants, including
parsley, paper mulberry and chamomile.194 Owing to the superiority of non-mutagenesis and
low intrinsic toxicity,198 apigenin has received great attention as a potential pharmaceutical
agent for benefiting human health. The potential mechanisms of apigenin acting as a cancer
suppressor are recognized for targeting diverse molecules and modulating versatile kinase
pathways, including promoting cell cycle arrest,199 inducing apoptosis,200-204 inhibiting
mutagenesis,205 and suppressing signal transduction

189,196,197

. It was reported that apigenin

induced ERK and p38MAPK pathway, but ineffective on the Jun kinase activity in HCT-116
cells.206 Apigenin was able to suppress the Wnt/β-catenin signaling pathway in colon cancer
cell, thereby inhibiting cell growth, migration, and invasion.207,

208

Apigenin reduced the

proliferation of colorectal cancer cells via arresting cell cycle at the G2/M phase along with a
decreased expression of cyclin B1.209 Besides, an in vivo anti-tumorigenic study using a
carcinogen-induced mice model showed that apigenin was capable of reducing ACF formation,
the early preneoplastic lesions in colonic mucosa.210
1.3.4.2 Role of apigenin in chronic inflammation
The protective effects of apigenin on chronic inflammation have also been well
established. Studies showed that apigenin inhibited the production of cytokines,211 suppressed
NO production in LPS-induced macrophages,212 and blocked the collagenase activity that is
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involved in rheumatoid arthritis.213 Apigenin exhibited anti-inflammatory activity against
ulcerative colitis (UC) in C57BL/6J mice in mechanisms involving the inhibition of
inflammatory cytokines, COX-2 expression, and the reduction in immune cell infiltration in
colonic tissues.214 Apigenin also served as a potent therapeutic agent in a murine dextran
sulphate sodium (DSS) colitis model through the reduction of matrix metalloproteinase (MMP3) level.215
1.3.4.3 Major limitations of apigenin
Despite the profound therapeutic benefits given above, apigenin has a very low solubility
in water (1.35 µg/mL).216 The highest aqueous solubility reported is only 2.16 µg/mL at pH =
7.5,217 leading to poor intestinal absorption. Apigenin is extensively metabolized after oral
administration and is mainly eliminated by the first-pass metabolism via glucuronidation and
sulfation in human bodies.161, 218 The rapid metabolism causes a considerable accumulation of
conjugates in the systemic circulation and thereby causes low bioavailability.219 Taken together,
the improvement of solubility and bioavailability is urgently required for developing
applications of apigenin.
1.4 Synergistic interactions between bioactive compounds
Additive and synergistic interactions of multiple phytochemicals present in fruits and
vegetables are suggested for their health benefits, resulting the recommendation of consuming
whole foods.220 This interesting “whole foods” theory has boosted numerous studies focusing
on the achievement of synergistic health beneficial effects by combinations of bioactive
compounds. Combinations of two or more purified bioactive agents or phytochemical-enriched
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plant extracts can modulate the antioxidant, anti-inflammatory and anti-cancer activities, as
well as the bioavailability and in vivo activity of each component. Mixtures of components can
produce additive, synergistic or antagonistic effects. When the effectiveness of combinations
is equal to the sum of individual components in the mixture, such interactions are additive;
whereas the greater or less effects of combinations than the additive effects result in synergistic
or antagonistic interactions.221 These interactions are always analyzed by the combination
index (CI), as CI > 1, = 1, < 1 represents antagonism, synergism, and addition effects,
respectively.222
1.4.1 Synergistic anticancer effects of dietary compounds
Current cancer chemotherapy has resulted in severe side effects and drug resistance.
Therefore, combination of different naturally occurring compounds has been employed to treat
different cancers, to potentially reduce drug dosages and alleviate the side effects of one drug,
to overcome drug resistance, as well as to potentiate the therapeutic outcome by targeting
multiple signal transduction pathways.223, 224 Studies have reported that EGCG synergistically
inhibited cancer cell viability and migration, induced apoptosis and suppressed angiogenesis
when combined with other natural molecules, such as ascorbic acid, curcumin, quercetin and
proanthocyanidins.225-227 Besides, a study in patients with familial adenomatous polyposis
reported that the therapy combining curcumin and quercetin reduced the number and size of
polyps from baseline and the adverse reactions were negligible.228 Mixtures of resveratrol,
chrysin and curcumin exerted synergistic anti-proliferative activity against Caco-2 colon
cancer cells.229 Likewise, blends of grape seed extracts and resveratrol enhanced the
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suppression of HCT-116 colon carcinogenic cells.230 The above studies suggest that mixtures
of bioactives with similar or complementary anti-cancer mechanisms can be studied for
potential synergy in the anti-cancer efficacy.
1.4.2 Synergistic anti-inflammatory activities of dietary compounds
Due to the complexity of inflammatory process, several combinations of dietary
compounds attempted to enhance the efficiency of inflammation treatments. For instance,
synergistic protective effects occurred in LPS-induced RAW 264.7 cells when combined
luteolin with tangeretin.231 Combinations of polyunsaturated fatty acids (DHA or EPA) with a
low dose of curcumin have been found to synergistically inhibit NO production, and suppress
expressions of prostaglandin E2 (PGE2), iNOS, COX-2, 5-lipoxygenase (5-LOX) and cPLA2
in LPS-activated RAW 264.7 macrophages.202 Different combinations of polyphenolic
compounds, including nobiletin and sulforaphane, lycopene, lutein, β-carotene, and carnosic
acid have also shown synergistic effects by modulating various inflammatory mediators in
LPS-induced RAW264.7 cells117,

232

The synergistic anti-inflammation activity of such

polyphenol combinations can result from multi-target effects of the individual compounds that
are otherwise impossible for a single component.
In addition to anticancer and anti-inflammatory effects, combination of phytochemicals
may also result in other biological changes, such as the antioxidant activity and the
bioavailability of individual components. Hyperoside acted in synergy with EGC on
ABTS· and DPPH· radical scavenging activities.233 Besides, β-carotene was found to increase
the bioavailability of lycopene in human plasma.234 Some natural molecules such as caffeine,
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genestein, piperine, and quercetin, were also found to enhance the bioavailability of EGCG in
mice.235-238 Overall, combinations of bioactive ingredients could induce changes in biological
activities and bioavailability of the component. Constructing such combination systems with
synergistic biological benefits may serve as effective strategy to deal with cancers and chronic
inflammation.

1.5 Nanoencapsulation systems and underlying problems
Given the low water solubility and bioavailability of many hydrophobic dietary
polyphenols limiting their therapeutic efficacy and further applications, nanoencapsulation has
appeared as an innovative and effective strategy to address these challenges. A number of
nanoencapsulation systems have been developed, including emulsions, liposomes, micelles,
polymeric nanoparticles, inclusion complexes, and nanocrystals. Their developments,
effectiveness, and underlying problems are specifically discussed.
1.5.1 Emulsions
Emulsions are thermodynamically unstable dispersions typically formulated by mixing
two immiscible liquids in the presence of surfactants with droplet dimensions of 0.1 to 100
μm.188, 239, 240 According to the droplet size, nanoemulsions are further defined as dimensions
less than 100 nm.241 Emulsion structures are differentiated from the spatial distribution of the
oil and water phases. Oil-in-water (O/W) emulsion refers to the system consists of oil droplets
dispersed in the water phase, whereas water-in-oil (W/O) emulsion is formed through the
aqueous solution dispersed in oil phase.242 However, when exposed to environment stresses,
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such as extreme temperatures, pH values, and salt concentrations, simple emulsions are often
physical instable due to coalescence or Ostwald ripening.243 Thus, more sophisticated multiple
systems have been developed, such as water-in-oil-in-water (W/O/W) emulsions, oil-in-waterin-oil (O/W/O) emulsions.242, 243 Distinguished from conventional emulsions, microemulsions
are isotropic and thermodynamically stable systems with dispersed droplet diameters varied
from 10 to 50 nm.240 Usually, nanoemulsions are typically resulted from high-energy methods,
such as homogenization, microfluidization or sonication,239,

244

while microemulsions are

formed spontaneously by self-assembly with a relatively higher amount of surfactants.188, 245
Emulsion-based delivery systems are widely applied to encapsulate lipophilic or
hydrophilic ingredients, protecting them against harsh environmental factors, and improving
biological activities.243, 246 For instance, degradation of curcumin at pH 5.9 was prevented by
nanoencapsulation into nanoemulsions containing Tween 80, lecithin, ethyl oleate, and water
during two month storage.247 In comparison to the free state curcumin, the resulted
nanoemulsions with droplet size of 114 nm resulted in a 1400-fold increment of the solubility.
Quercetin formulated in nanoemulsions increased the bioaccessibility by two times than that
solubilized in bulk oils.188 Olive leaf phenolic extracts were incorporated in W/O/W multiple
emulsions stabilized by WPC and pectin.248,

249

The antioxidant activity of the resulted

emulsion in soybean oil was enhanced compared with the non-encapsulated phenolic extracts.
Besides, food-grade microemulsions made of lecithin, caprylic/capri triglycerides, isopropyl
myristate, alcohols, and water were produced to nanoencapsulate natural antioxidants, such as
gallic acid, p-hydroxybenzoic acid, protocatechuic acid, and tyrosol, with droplet size of
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smaller than 10 nm.250 The increased bioavailability of diacylglycerol oils dissolved in
microemulsions have also been reported.251 Nevertheless, the high cost of energy input and the
large amount of surfactants or co-surfactants which may lead to mucosal toxicity are the major
disadvantages existing in these systems.
1.5.2 Solid lipid nanoparticles and nanostructured lipid carriers
Similar to conventional O/W emulsions, solid lipid nanoparticles (SLNs) also consist of a
hydrophobic core and a hydrophilic shell, however, the liquid oils are replaced by the solid
state lipids, including fatty acids (e.g. decanoic acid and stearic acid), triglycerides (e.g.,
tristearine), waxes (e.g., cetyl palmitate), and steroids (e.g. cholesterol).252, 253 Surfactants or
co-surfactants are applied to stabilize the lipid phase.239 SLNs are usually fabricated by initially
preparing an O/W emulsion using different strategies at elevated temperatures above the
melting point of the oil phase, then cooling down to promote lipid crystallization.244, 254 Highenergy methods including high shear homogenization, high-pressure homogenization (hot and
cold), and ultrasonication are commonly used to yield SLNs.188, 253, 255 SLNs can also be
prepared

by

laboratory-scale

approaches

such

as

phase

inversion

and

solvent

emulsification/evaporation.253, 256 Encapsulating lipophilic compounds into the solid lipid core
have been reported to increase the stability, reduce chemical degradation, and prolong the
release of components since the solidified lipid phase is able to inhibit molecular diffusion.239,
246, 257

For example, enhanced refrigerated and ambient storage stability as well as

bioavailability of curcumin were reported after incorporating into SLNs which were prepared
by high shear homogenization and ultrasonication followed by coating with chitosan.258
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Resveratrol was loaded into SLNs formulated with surfactants of Tween 80 and polyvinyl
alcohol (PVA).259 The resulted particles showed a sustained release of resveratrol and
promising anti-neoplastic activity in brain tissues.
Despite the widely use of SLNs as delivery systems, SLNs suffer a number of limitations,
such as the low ingredient loading capacity, possibility of compound leakage during storage,
and susceptibility of particle aggregation.244, 260 As for this, nanostructure lipid carriers (NLCs)
with a mixture of solid–liquid lipids that crystallize into more irregular structures were
developed.260,

261

Compared with the highly ordered solid structure formed in SLNs, the

irregular solid lipid phase in NLCs resulted in more effective encapsulation of bioactive
compounds, with a higher loading capacity, higher encapsulation efficiency, and higher
bioavailability.244 In a study, resveratrol were incorporated in both SLNs and NLCs by
homogenization. SLNs were developed using glyceryl behenate while NLCs were prepared by
using liquid migliol oil as a replacement of a part of the solid lipid. The resulted NLCs were
found to have 18% higher encapsulation efficiency of resveratrol and smaller particle sizes,
which promote the superiority of NLCs for further dermal applications.262 Curcumin loaded
NLCs showed high encapsulation efficiency of 91.76% with a nanometric size of 263.9 nm.263
Enhanced skin permeation, anti-oxidation, and anti-inflammation of quercetin were also
reported in a NLC system prepared by evaporation-solidification at low temperature.264
1.5.3 Liposomes
Liposomes are spherical vesicles self-assembled from phospholipid bilayers surrounding
an aqueous core.244, 245 The interactions between the amphiphilic phospholipids and the water
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molecules driving the hydrophilic heads exposed to the interior aqueous phase and exterior
environment while the hydrophobic fatty acid tails to the bilayer are accounting for the
formation of liposomes.253 Due to the biphasic character, liposomes are able to deliver both
hydrophilic and hydrophobic bioactive agents.265 Besides, the nanometric size of liposomes
which refers to as nanoliposomes have higher potential to improve the bioavailability of
entrapped compounds due to the larger interfacial area contacting with biological tissues
produced by the smaller size.266 Consequently, higher energy input is required to reduce the
size of liposomes. Nanoliposomes are commonly produced by high pressure homogenization,
microfluidization, extrusion, and sonication.239, 253 Liposomes have been evidenced to enhance
the bioactivity and bioavailability of phenolic compounds by a number of studies. In a study,
quercetin loaded in liposomes and administered by intranasal administration showed anxiolytic
and cognitive beneficial effects when compared to pristine quercetin administered orally.267
Apigenin-loaded liposomes, fabricated by a lipid film hydration method in the presence of
methanol, showed enhanced chemotherapeutic efficacy against colorectal cancer based on
flavone-membrane interactions.268 Nanoliposomes were also carried out for encapsulation of
essential fatty acids to protect them against oxidation and increase their bioavailability.269, 270
Due to the susceptibility to oxidation and physical instability, liposomes are always coated by
polymers to achieve steric stabilization.239, 271 As an example, curcumin loaded nanoliposomes
coated with chitosan were demonstrated to protect curcumin against digestion in mouth and
gastric tract in vitro, and promote absorption in the small intestine and thereby enhancing the
bioavailability.272 Despite these reports, the residual organic solvent, the high cost of the
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phospholipids and surfactants are potential problems restricting the wide applications of
liposomes in food systems.
1.5.4 Micelles
Micelles are thermodynamically stable systems formed spontaneously when the
concentration of surfactants exceeds their critical micelle concentration (CMC) in water.188, 239
Recently, polymeric micelles that composed of amphiphilic block-copolymers are gaining
popularity as delivery systems.239 The hydrophobic and hydrophilic monomer units existed in
the molecule formulate a core-shell micelle structure which can accommodate lipophilic drugs
to the hydrophobic core, thereby increasing the solubility, enhancing the permeability and
protecting them from the biological environments such as the gastrointestinal tract.239, 271, 273
For instance, apigenin-loaded polymeric micelles made of Pluronic P123 and Solutol HS 15
were reported to improve cytotoxicity against HepG2 and MCF-7 cancer cells.274 It has been
found that the solubility of curcumin was greatly increased after incorporation in polymeric
micelles composed of methoxy poly (ethylene glycol)-block-polycaprolactone diblock
copolymers (MePEG-b-PCL).275 Quercetin was delivered by a nanomicelle prepared by the
diblock copolymer of polyethylene glycol (PEG)-derivatized phosphatidylethanolamine (PE)
and the micellar formulation presented an enhanced anti-cancer activity both in in vitro A 549
lung cancer cells and in vivo murine xenograft model.276
1.5.5 Polymeric nanoparticles
Polymeric nanoparticles are colloidal delivery systems fabricated from food proteins and
polysaccharides, as well as synthetic polymers such as polylactide-co-glycolide (PLGA),
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polyglycolic acid (PGA), and polylactic acid (PLA).253, 277 Due to the high biodegradability,
biocompatibility, low toxicity, slow and sustained drug release, polymer-based nanoparticles
have been regarded as popular delivery systems for the encapsulation of various therapeutic
ingredients.253,

278

Incorporation of curcumin into zein nanoparticles with 100-150 nm

increased the stability of curcumin against different pH values and UV irradiation.279 Casein
nanoparticles were developed to protect vitamin D from thermal treatment as well as increase
the long-term cold storage stability and bioavailability.280 Quercetin loaded PLA nanoparticles
were prepared by a simple evaporation method.281 Besides, apigenin encapsulated in PLGA
nanoparticles with a dimension of about 100 nm, prepared by solvent displacement, were
investigated for anti-proliferative potentials in A375 cells in vitro.282 Chitosan nanoparticles
are of great interest being used as an absorption enhancer due to its positive charge and mucous
adhesiveness.246, 283, 284 In an attempt to encapsulate EGCG into peptide/chitosan nanoparticles,
more than two-fold enhancement permeation rate across CaCO-2 cells was observed.285 Thus,
it is clear that the versatile polymeric nanoparticles have great potential to deliver functional
dietary components, however, the residual organic solvent produced during the formation
process such as solvent evaporation,253 nanoprecipitation,277 and desolvation244 may possess
potential toxicity.
1.5.6 Inclusion complexes
In molecular inclusion, encapsulated molecules are entrapped by the shell materials,
generally cyclodextrins (CDs), through hydrogen bonding, van der Waals forces or
hydrophobic interactions.188, 242, 286 CDs are naturally occurring cyclic oligosaccharides derived
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from starch by bacterial enzymatic conversion, consisting of six, seven or eight glucopyranose
units known as α-, β-, and γ-CDs, respectively.188, 253, 287 β-CD is the most commonly applied
CD for encapsulation.242 The molecular structure of CDs is characterized with an internal
hydrophobic cavity and an external hydrophilic rim.288 which ensure their ability to encapsulate
poorly water soluble phytochemicals into the apolar interior part through hydrophobic
interactions, thereby increasing their aqueous solubility, stability and bioavailability.242, 244 Kim
et al. investigated the inclusion of apigenin in (2-hydroxypropyl)-β-cyclodextrin (HP-β-CD),
and increased the solubility by 11.5 times.289 Significant improvement of the solubility and
anti-proliferative activity against human erythroleukaemia and cervix cancer cells of quercetin
occurred after inclusion into the sulfobutyl ether-7β-cyclodextrin.290 Curcumin-loaded β-CD
was prepared using a solvent evaporation technique. Compared with the free curcumin, the
resulted complex showed increased stability at pH 7.4, 37℃ and anti-inflammatory effects in
prostate cancer cell lines.291 Apart from phytochemicals, volatile organic molecules have been
encapsulated in inclusion complexes to mask odors and flavors, or preserve aromas.286
1.5.7 Nanocrystals
Nanocrystals are another approach widely used to overcome the solubility issue of
bioactive compounds. Main advantages of nanocrystals are not only the increased drug surface
area, the increased dissolution rate, but also the increased penetration and cellular uptake by
epithelium cells due to the small particle dimensions, which significantly improve the
bioavailability of phytochemicals.292-294 For example, loading quercetin in nanosuspension
yielded a 70-fold increment of the solubility, and the clearance rate in plasma was significantly
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reduced with an increased bioavailability of quercetin.295 Nanocrystals are commonly produced
by the “top-down” technology, for example, bead milling or high pressure homogenization.288,
296

These methods require no harsh solvents, however, the high energy input, high cost, and

low power efficiency are underlying problems remain to be resolved.
In conclusion, in spite of extensive studies, many of these approaches remain problematic
for food applications. In this respect, a constant demand for new types of non-toxic nanocarriers
and low-cost, low-energy technologies are still significantly needed.

1.6 Bovine milk proteins as effective encapsulation carriers
Food proteins provide nutrition and functions.297 Proteins isolated from bovine milk are
chemically and structurally versatile, and are promising natural nano-vehicles for delivering
bioactives.297, 298 Bovine milk proteins consist of two major categories: caseins and whey
proteins (Table 1-1).298
1.6.1 Caseins
Caseins account for almost 80% of the total bovine milk proteins and are inexpensive,
widely available,298

biocompatible, and biodegradable.297 Caseins are composed of

approximate 94% protein and 6% minerals known as colloidal calcium phosphate.299 Mainly
four types of caseins, αs1-, αs2-, β- and κ-casein exist in bovine milk, differing in amino acid,
number of phosphorus atoms, content of carbohydrate, functional properties, and genetic
variations.300-302 αs1-, αs2-, and β-casein are phosphoproteins with serine-phosphate residues for
calcium binding.303 In particular, αs1-casein has the highest negative charge and phosphate
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content; αs2-casein is more sensitive to Ca2+ than others, whereas β-casein has the highest
portion of prolines (17% proline residues).299 κ-casein, on the other hand, is a glycoprotein with
two cysteines and is able to form disulfide bridges.304 Due to the high levels of hydrophobic
and hydrophilic amino acid residues, caseins are amphiphilic proteins and are naturally selfassembled into micelles in aqueous solutions with an average size of 150-200 nm.304, 305 Casein
micelles are proposed to be held together by calcium phosphate nanoclusters binding with
phosphopeptides in the core and stabilized by the charged surface coverage with the
hydrophilic segment known as glycomacropeptide of κ-casein, providing electrostatic and
steric repulsions.306-308 Caseins are in open structure due to the high content of proline.303 The
highly random and flexible structure enables their thermal stability, however, results in a
susceptibility to changes in temperature, pH, ionic strength, and high hydrostatic pressure
which will alter their size distribution.302 Lowering temperature favors the dissociation of
casein micelles.309 Casein micelles can also be disrupted under alkaline conditions, but
aggregate and precipitate at isoelectric point of 4.6–4.8, due to the alteration of calcium
phosphate

solubility and

electrostatic

interactions.300,

310

Besides,

high

pressure

homogenization,311 hot ethanol (> 35%) aqueous solution with above 60 ℃ are also able to
disrupt the micellar structure.312, 313
1.6.2 Whey proteins
In contrast, whey proteins constitute the rest 20% of bovine milk proteins and are
generally produced as a co-product of the cheese industry.314 They are typically globular
proteins of variable compositions and diverse biological functions.240 The functional properties
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of commercial whey protein products are mainly controlled by the predominant whey protein,
β-lactoglobulin (β-lg).315 β-lg is a small globular protein made up of 162 amino acids.299 The
structure of β-lg is characterized as a β-barrel calyx folded up by eight antiparallel β-strands
(strands A-H), an important part on the dimer interface formed by the ninth strand (strand I),
and an α-helix on the outer surface.299, 316 Five cysteines exist in the β-lg sequence, resulting in
two disulfide bonds and a free thiol group which is responsible for the pH dependent activity
and plays an important role in protein aggregation and denaturation.297, 316 It is mainly found
as dimers at neutral pH, whereas at acidic pH below 3.5 or above 7.5, β-lg always dissociates
into monomers due to the electrostatic repulsions between the subunits.299,

316

Due to the

stability of globular conformation in acidic conditions, β-lg is resistant to peptic degradation,243
which makes it capable to protect bioactives in the gastric tract.317 As the second most abundant
whey protein, α-lactalbumin (α-la) is a smaller globular metalloprotein stabilized by four
disulfide bridges.318 α-la is partially responsible for the synthesis of lactose in the mammary
gland.319 In addition, minor whey protein, bovine serum albumin (BSA), is a larger protein with
582 amino acids and structurally contains a main α-helix, 17 intramolecular disulfide bonds,
and a free thiol.304, 320, 321 It is found both in blood serum and milk, with the capability to bind
and deliver various small ligands.304 Bovine lactoferrin is a monomeric globular glycoprotein
with around 700 amino acid residues, belonging to the transferrin family.299, 304 Lactoferrin
consists of two lobes which have iron binding ability.299 It is in a broad spectrum of biological
activities, such as antimicrobial, anti-inflammatory, anti-cancer, immunomodulatory, and
enzymatic activities.299, 322
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1.6.3 Unique physicochemical properties and structures of bovine milk proteins
In addition to the non-toxicity and high nutritious value, dairy proteins are unique in many
structural and physicochemical properties which confer them as natural nanovehicles to deliver
drugs and nutrients. These attributes include binding of hydrophobic compounds, excellent
self-assembly properties, superior gelation properties, as well as surface activities.
1.6.3.1 Binding hydrophobic molecules
Bovine milk proteins have gained special interest for transporting bioactive molecules due
to their binding properties.304,

323

Mechanisms involved in the binding reactions include

covalent and noncovalent interactions.303 Covalent bonds commonly lead to irreversible
bindings of hydrophobic agents to free reactive nucleophilic groups such as amino (–NH2) and
thiol (–SH) groups on the surface or inside cavities of proteins.324, 325 Noncovalent interactions
including hydrophobic interactions, van der Waals forces, and hydrogen bonds are more
common compared to covalent bonds and generally result in the reversible binding reactions.304
Proline residues of proteins are well-known primary binding sites for various polyphenols.326
Caseins, proline-rich proteins with open and no fixed tertiary structures, highly tend to
associate with phenolic compounds as well as other ligands, predominantly via hydrophobic
interactions and hydrogen-bonding.246, 326, 327 For instance, vitamin D has been successfully
nanoencapsulated into β-casein micelles possibly due to adhesion of hydrophobic vitamin D to
the hydrophobic residues of caseins.328 Sodium caseinate has been reported as a carrier for ω3 polyunsaturated fatty acids. Each caseinate molecule can bind 3 to 4 DHA molecules; the
DHA-loaded casein nanoparticles showed good colloidal stability with a size of approximately
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300 nm.329 Apart from caseins, β-lg also acts as a good carrier for various hydrophobic
molecules.299 As a member of lipocalins superfamily, β-lg has three possible binding sites: a
central β-barrel calyx with hydrophobic interior as the main site, the secondary site on the
external surface of the β-barrel near the α-helix, and the ternary site at the dimmer interface.299,
316, 330

As for this, numerous studies have confirmed the binding and transporting role of β-lg

for many hydrophobic compounds. One β-lg molecule was found to be able to bind three folic
acid molecules through hydrophobic interactions.331 Besides the native β-LG, thermally
modified β-LG can also be used for the development of delivery systems. β-lg binds with
phenolic phytochemicals, including resveratrol and epigallocatechin gallate (EGCG), and can
be strengthened after prior heat denaturation of the protein to expose more hydrophobic amino
acid residues.332, 333 Compared with β-lg, α-la gained less research as vehicles, however, was
still demonstrated to bind polyphenols such as genistein and kaempferol mainly via hydrogen
bonds.334 In addition, BSA is always a natural carrier for hydrophobic vitamins and
hormones.324
1.6.3.2 Self-assembly properties
Molecular self-assembly plays quite an important role in the nanotechnology. As for
caseins, self-assembly is well documented as micelle formation. Structurally, casein micelles
have a hydrophobic core and a hydrophilic-charged κ-CN layer, which are able to encapsulate
lipophilic compounds via hydrophobic interactions.299,

335

β-casein micelles have been

suggested to deliver curcumin, for enhanced solubility as well as bioavailability and antioxidant
activity.336 The cytotoxic effects of curcumin on MCF7 cells was demonstrated to be enhanced
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in the presence of β-casein micelles.337 Reconstituted casein micelles were achieved by
applying high pressure homogenization followed by depressurization, and were used to
encapsulate vitamin D2 to protect against degradation under UV-light.338 β-carotene was also
incorporated in reassembled casein micelles to elude the degradation induced by industrial
process such as pasteurization and high hydrostatic pressure.339 Besides, self-assembly of β-lg
was reported recently in the presence of lysozyme (Lyso) using electrostatic interactions
between the two oppositely charged proteins.340 The developed β-lg/Lyso microspheres were
able to efficiently entrap vitamin D3 with an encapsulation efficiency of 90.8 ± 4.8%.
Additionally, novel nanotubes were formed by self-assembling of enzymatically hydrolyzed αla.341
1.6.3.3 Gelling properties
Gelation of food proteins enables the development of colloidal particles with the
embedded bioactive cores, and is extensively studied.323, 342 The desired gelled structures of
milk proteins can be induced by acid, enzymes, or thermal treatment.324 Acid gelation is based
on the isoelectric point (pI) precipitation of caseins.304 Due to the lack of rigid tertiary structures,
caseins are promising candidates for enzymatic cross-linking by transglutaminase (TGase),
which covalently link the glutamine residues in the peptides with the lysine residue.302 These
heat-free gelation processes are advantageous for heat labile bioactives, such as probiotics.343,
344

Genipin, a naturally occurring cross-linking agent, was also reported to induce heat-free

gelation of caseins.345
Heat-induced gelation usually results from denaturation and unfolding of proteins, via
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hydrophobic interactions.304 In contrast to caseins, whey proteins are prone to thermal
treatment and undergo partially unfold and associate with each other or lipophilic molecules
through hydrophobic attractions when temperatures are above 70 °C.346 Hydrogels induced by
heating whey protein concentrate have been used as carriers for caffeine.318 It is noteworthy
that whey proteins are exceptional due to the ability to form cold-set gelation by the addition
of cations, preferably Ca2+ ions to the preheated whey protein solutions which is at pH far from
the pI and in low ionic strength, or lowering pH to the pI.302, 304, 347 The cold-induced gelation
network has been successfully used to encapsulate some heat sensitive microorganisms, for
example yeasts, to maintain their viability and growth capability.348
1.6.3.4 Surface activity
Bovine milk proteins possess excellent surface activities and emulsifying properties due
to their amphiphilic structures, thereby playing important roles in emulsion-based delivery
systems.324, 349 They are able to adsorb at the oil-water interface and stabilize emulsions.304 The
surface properties are influenced by various factors, such as the structure and flexibility of
proteins, state of aggregation, as well as the ionic strength, the temperature and the pH of the
environment.304 With a high flexibility, caseins are suitable emulsifiers and emulsion
stabilizers.350 Sodium caseinate was found to have a better stabilization ability than whey
protein in an O/W emulsion composed of palm kernel oil and sunflower oil.351 The entrapped
β-carotene in this system achieved an increased stability with higher protein concentrations. In
another study, β-lg and lactoferrin stabilized emulsion based carrier system for β-carotene.352
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1.6.4 Bovine milk protein-based particles as delivery systems
The unique physicochemical characteristics and special nanostructures as detailed above
have facilitated the functionality of bovine milk proteins in delivery tasks. A wide variety of
hydrophobic bioactives have been entrapped into milk protein-based colloidal particles, such
as polyphenols, vitamins, and polyunsaturated fatty acids.298, 353 Spherical particles formed by
hydrophobic interactions between β-carotene and casein-grafted dextran were stable against
dilution, pH change, oxidation, and long-term storage.304 Vitamin B12 as a model bioactive has
also been incorporated into the enzyme-assisted novel casein hydrogels under mild conditions
and showed a prolonged release behavior.354 Besides, resveratrol was investigated to bind with
β-lg to significantly increase the solubility, and bioavailability.355 Caffeine was encapsulated
using a desolvation method by preheating the β-lg solution to 60℃, with an average particle
size about 60 nm.355 It was also reported that β-lg in various conditions served as a promising
matrix for the encapsulation of anthocyanins from sour cherry extract.356 Whey protein isolate
based nanoparticles was successfully applied for encapsulation of vitamin D3, with the
protection from oxygen.357

1.7 Hypothesis and objectives
As given above, apigenin has gained special attention due to its relatively low intrinsic
toxicity, non-mutagenic property, and promising health beneficial effects, especially in the
reduction of cancer incidence and attenuation of chronic inflammation. However, the poor
water solubility and low bioavailability have hindered further applications of apigenin.

39

Therefore, the long-term goal of the current research is to develop food biopolymer-based
nanodelivery systems to improve the solubility, bioavailability, and thereby enhance the
therapeutic activity of apigenin.
The first objective of this dissertation is to nanoencapsulate apigenin in bovine milk
proteins. The working hypothesis is that nanoencapsulation can improve the bioavailability and
anti-colorectal cancer activity of apigenin both in vitro and in vivo. Three tasks were conducted
to address this hypothesis.
Task 1 is to fabricate organic-solvent free and whey protein isolate (WPI)-based nanodelivery
system, and characterize physicochemical properties of nanoparticles (Chapter 2).
Task 2 is to investigate the anti-colorectal cancer activities of nanodelivered apigenin against
human colon cancer cells (HCT-116 and HT-29) in vitro (Chapter 2).
Task 3 is to evaluate the oral bioavailability and in vivo anti-colorectal cancer efficacy of
nanodelivered apigenin in Apcmin+ mouse model (Chapter 3).

The second objective is to test the hypothesis that co-encapsulating apigenin together with
curcumin can enhance the synergistic anti-inflammatory effects in LPS-stimulated RAW 264.7
macrophages. The hypothesis was tested in two tasks presented in chapter 4.
Task 1 is to coencapsulate apigenin and curcumin with sodium caseinate (NaCas), followed by
characterizing physicochemical properties of dispersions.
Task 2 is to investigate the potential synergistic anti-inflammatory activity of apigenin and
curcumin in both simple mixtures and coencapsulated forms.
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The present study may provide a better understanding of the biological fate of
nanodelivered apigenin that may be used to combat colorectal carcinogenesis and
macrophages-based inflammation.
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Appendix
Table 1-1. Composition of proteins in bovine milk1, 2
Protein
Caseins

Whey proteins

αs1-casein
αs2-casein
β-casein
κ-casein
β-lactoglobulin
α-lactalbumin
Bovine serum
albumin (BSA)
Immunoglobulins
(mainly IgG, IgM)
Lactoferrin

Content in milk (g/l) Molecular weight (kDa)
12-15
22.1-23.7
3-4
25.2-25.4
9-11
23.9-24.1
3-4
19.0
2-4
18.3
1-1.5
14.2

Fat globule
membrane proteins
Total milk proteins

0.1-0.4

66

0.6-1.0

150, 900

~0.1

80

~0.4

13-200

30-35
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Figure 1-1. Molecular structure of apigenin (4’,5,7-trihydroxyflavone).
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Chapter 2. Nanoencapsulation of apigenin with whey protein isolate:
physicochemical properties and in vitro activities against colorectal
cancer cells

79

2.1 Abstract
Incorporating lipophilic phytochemicals with anti-cancer activities in functional
beverages requires an appropriate nanoencapsulation technology. The present objective was to
encapsulate apigenin, a compound present in many fruits and vegetables, with whey protein
isolate (WPI), utilizing a pH-cycle method, and subsequently characterize physicochemical
properties of the nanoencapsulated apigenin and the in vitro anticancer activities against human
colorectal cancer cells (HCT-116 & HT-29). Up to 2.0 mg/mL of apigenin was
nanoencapsulated with 1.0% w/v WPI successfully, with an encapsulation efficiency of up to
98.38% and loading capacity of up to 195.78 mg/g-WPI. Nanodispersions maintained stable
after 30-day ambient storage with the particle hydrodynamic diameter of 240 nm. The obtained
nanoparticles exhibited near-spherical morphology under atomic force microscopy. Results
from differential scanning calorimetry showed amorphous structures of apigenin verifying
encapsulation. Hydrogen bonds and hydrophobic interactions between apigenin and WPI were
confirmed in Fourier transform infrared spectroscopy. Anti-proliferative activities against
HCT-116 and HT-29 were studied with 5, 10 and 20 μM of nanoencapsulated or dimethyl
sulfoxide (DMSO)-dissolved apigenin, before and after in vitro digestions. Results showed that
nanoencapsulation and in vitro digestion did not negatively affect the growth inhibitory activity
of apigenin. Cellular uptake of apigenin was quantified using HPLC after lysing cells. Apigenin
accumulated in HCT-116 and HT-29 treated with 20 μM DMSO-dissolved-apigenin was 0.37
and 0.08 μg/mg-protein, respectively, which was enhanced to 2.51 and 2.75 μg/mg-protein for
the 20 μM nanoencapsulated apigenin. Cell cycle distribution and apoptotic cells were further
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analyzed by flow cytometry. Results suggested that the growth inhibitory activity of apigenin
was possibly due to the induction of cell apoptosis, and nanoencapsulation enhanced the proapoptotic effects. Therefore, the studied scalable nanoencapsulation system may be significant
to incorporate lipophilic phytochemicals in functional beverages for disease prevention.

Keywords: apigenin, whey protein isolate, pH-cycle, nanoencapsulation, in vitro anticancer
activity
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2.2 Introduction
Natural polyphenols, occurring as the secondary plant metabolites, have attracted
increasing attentions for decades due to their versatile biological activities.3, 4 Polyphenols from
edible plants, when studied at a physiologically relevant concentration, have been reported for
low or no toxicity on human organs and cells.5 Apigenin (4’,5,7-trihydroxyflavone) is one of
the most investigated polyphenols and is abundantly presented in numerous dietary plants such
as celery, parsley, onions, chamomile.6 Apigenin is believed to exert a broad spectrum of health
beneficial effects, including free radical scavenging properties, and anti-inflammatory
activities.7 More importantly, owing to non-mutagenesis and relatively low toxicity, apigenin
has shown promising preventive and therapeutic potential against cancers.8 For example, the
potential chemotherapeutic effects of apigenin have been reported for numerous human colon
cancer cell lines via inhibition of cell proliferation,9 promotion of cell cycle arrest,10 and
induction of cell apoptosis.11 However, the high hydrophobicity of apigenin results in a very
low water solubility, with the highest aqueous solubility of only 2.16 µg/mL at pH = 7.5,12
leading to a poor absorption in the gastrointestinal tract. In addition, the rapid metabolism and
elimination via glucuronidation and sulfation in vivo lead to a low bioavailability of apigenin,
which limits the therapeutic efficacy.13 Therefore, improvement of solubility and
bioavailability is of primary significance for further development and application of apigenin.
Nanotechnology is a potential approach to improve solubility and enhance bioavailability
and bioactivity of lipophilic polyphenols. Recently, numerous studies set their aims at
developing appropriate delivery systems to address the limitations of apigenin, such as
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liposomes prepared by lipid film hydration method,14 polymeric micelles made from Pluronic
P123 and Solutol HS 15,15 nanosuspensions prepared by high-pressure homogenization,16
nanocrystals fabricated using supercritical antisolvent process,17 and poly (lactic-co-glycolic
acid) (PLGA)-based nanoparticles.18 The usage of synthetic surfactants, the residual organic
solvent, and the presence of synthetic polymers in these studies may cause chronic toxicity and
be impractical in food applications. Besides, processes used to fabricate nanostructures may be
costly or difficult to scale up. To overcome these challenges, efforts to develop low-cost, and
low-energy processes and non-toxic delivery systems are needed to further exert the
pharmacological functions and therapeutic efficacy of apigenin.
A pH-cycle method, by first increasing a mixture to alkaline pH followed by lowering pH
to neutral conditions, has been successfully applied to encapsulate curcumin in sodium
caseinate in our research group.19 In addition, the high biodegradability, biocompatibility, nontoxicity, abundance, sustainability, low-cost and unique physicochemical properties of dairy
proteins have made them suitable as nanocarriers for delivering various bioactives.1,

20, 21

However, dairy proteins have not been studied to incorporate apigenin to enhance the solubility
and bioavailability.
The first objective of the current study was firstly to apply the pH-cycle method to
fabricate a low-cost, low energy, and organic solvent-free nanodelivery system of apigenin,
using whey protein isolate (WPI), and characterize physicochemical properties of the
optimized nanoparticles. The in vitro anticancer activities of nanoencapsulated apigenin were
investigated using human colon cancer cells (HCT-116 and HT-29) in the second objective.
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2.3 Materials and methods
2.3.1 Materials
Apigenin (>98%) was purchased from Indofine Chemical Co. Inc (Hillsborough, NJ,
USA). WPI was purchased from Hilmar Ingredients (Hilmar, CA, USA). Human colon cancer
cell lines HCT-116 and HT-29 were purchased from American Type Culture Collection
(Manassas, VA, USA). Growth media MEM 1X was purchased from Corning Inc. (Corning,
NY, USA). Fetal bovine serum (FBS) was purchased from Life Technologies (Carlsbad, CA,
USA). All other chemicals were obtained from Thermo Fisher Scientific (Pittsburgh, PA, USA)
unless otherwise stated.
2.3.2 Nanoencapsulation of apigenin
Nanoencapsulation of apigenin followed our previous work with some modifications.19
Experimentally, 1% w/v WPI was hydrated in deionized water overnight at 4 ℃, followed by
adding 0.6-2.0 mg/mL apigenin and adjusting pH to 13.0 using 2.0 M KOH solution. After
stirring for 5 min at ambient temperature (21 ℃) and adjusting the pH to 10.0, samples were
stirred for another 30 min at 21 ℃ before subsequent titration to pH 7.0 with 1.0 M HCl. The
unencapsulated apigenin was removed by centrifugation at 10,000 g for 10 min (Sorvall LYNX
6000 Centrifuge, Thermo Fisher Scientific, Waltham, MA, USA), and the supernatant was
collected as the nanodispersion. The precipitate was dissolved in DMSO to quantify the
encapsulation efficiency and loading capacity based on the absorbance at 337 nm and a
calibration curve that was established using standard solutions with various concentrations of
apigenin in DMSO.
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EE % =

𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐴𝑃 (𝑚𝑔) − 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐴𝑃 𝑖𝑛 𝑝𝑟𝑒𝑐𝑖𝑝𝑖𝑡𝑎𝑡𝑒 (𝑚𝑔)
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐴𝑃 (𝑚𝑔)

Loading capacity (mg/g) =

× 100

𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐴𝑃 (𝑚𝑔) − 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐴𝑃 𝑖𝑛 𝑝𝑟𝑒𝑐𝑖𝑝𝑖𝑡𝑎𝑡𝑒 (𝑚𝑔)
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑊𝑃𝐼 (𝑔)

Lyophilized samples (Model Advantage Plus EL-85, VirTis Company, Inc., Gardiner, NY,
USA) were additionally prepared for following experiments.
2.3.3 Physicochemical characterizations of nanoencapsulated apigenin
2.3.3.1 Dynamic light scattering (DLS) and zeta-potential
Particle size distributions of pH 7.0 dispersions added with 0.2% w/v sodium azide to
prevent microorganisms during 30-day ambient storage (21 °C) were measured using a
Zetasizer Nano-ZS series instrument (Malvern Instruments, Ltd., Worcestershire, UK). Zetapotential of nanodispersions and WPI solution that was also processed by the same pH-cycle
were also measured using the same instrument.
2.3.3.2 Atomic force microscopy (AFM)
The morphology of nanoparticles was studied using AFM. The nanodispersion prepared
with 2.0 mg/mL apigenin was diluted 200 times in deionized water, to an equivalent WPI
concentration of 50 μg/mL. After spreading 10 µL of the diluted sample on a freshly cleaved
mica sheet adhered on a sample disk, samples were dried overnight at ambient conditions
(21 ℃ ). The rectangular cantilever had an aluminum reflective coating on the backside
(ScanAsyst, Bruker Corp., Billerica, MA, USA). Topographical images were collected at the
scan area of 1.0 × 1.0 μm using a scanning speed of 1 Hz (multimode VIII microscope, Bruker
AXS, Billerica, MA, USA).
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2.3.3.3 Differential scanning calorimetry (DSC)
Thermal properties of lyophilized nanodispersion prepared with 2 mg/mL apigenin,
lyophilized WPI powder with the pH-cycle, and pristine apigenin were characterized with a
model Q2000 calorimeter (TA Instruments, New Castle, DE, USA). Around 3 mg powder was
placed in a hermetic aluminum pan that was then sealed before heating from 20 to 400 °C
followed by cooling from 400 to 25 °C at a constant rate of 10 °C/min, with nitrogen as a purge
gas at 50 mL/min.22
2.3.3.5 Fourier transform infrared (FTIR) spectroscopy
Possible intermolecular interactions between apigenin and WPI were investigated using
FTIR spectroscopy.23 The FTIR spectra of freeze-dried samples were recorded by preforming
64 scans over 400-4000 cm-1 with a resolution of 4 cm-1 (Spectrum Spotlight, PerkinElmer Inc.,
Waltham, MA, USA).
2.3.4 In vitro gastrointestinal digestion
In vitro gastrointestinal digestion was conducted following a previously reported method
with modifications.24 Specifically, 200 μL of apigenin pre-dissolved in DMSO at 20 mM, 500
μL of the nanodispersion prepared with 2.0 mg/mL apigenin, 500 μL of 1% w/v WPI processed
by the pH-cycle or 500 μL of 1% w/v unprocessed WPI was mixed with 6 mL of the simulated
gastric fluid, containing 1.5 mg/mL pepsin. After adjusting to pH 2.0 and incubating at 37 °C
in a water bath shaker (New Brunswick Scientific Co Inc., Edison, NJ, USA) for 2h (150 rpm),
the mixture was added with 4 mL of simulated intestinal fluid, containing 5 mg/mL pancreatin
and 5 mg/mL bile salts, adjusted to pH 7.0 with 1 M NaOH, and incubated for 4 h in the shaking
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water bath at 37 °C. The digestion was terminated by heating at 75 °C for 20 min to inactivate
enzymes. At the end of 2-h peptic and 4-h pancreatic digestions, 1 mL aliquots were sampled
for gel electrophoresis. The mixture samples after terminating the digestions were further used
in cell work.
2.3.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Unprocessed 1% w/v WPI, pH-cycle treated 1% w/v WPI, the nanodispersion prepared
with 2 mg/mL apigenin, and digested samples were mixed with an equal volume of Laemmli
buffer (Bio-Rad Laboratories, Inc., Hercules, CA, USA) containing 5% β-mercaptoethanol and
heated in boiling water for 5 min. Samples were loaded into wells of a 4–20% Mini-Protean
TGX gel (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and run in Bio-Rad
Tris/Glycine/SDS buffer for 30 min at 200 volts. After washing twice for 10 min each with
deionized (DI) water, the gel was incubated and stained with 50 mL of Bio-SafeTM Coomassie
G-250 blue dye for 1 h with gentle shaking. Thereafter, the gel was washed and destained with
DI water until the background became clear.
2.3.6 Cell culture and cell proliferation assay
Anti-proliferative activities of free or nanoencapsulated apigenin against human
colorectal cancer cells HCT-116 and HT-29 both before and after the simulated digestions were
evaluated. Human colorectal HCT-116 and HT-29 cells were obtained from the American Type
Culture Collection (Manassas, VA, USA), and cultured in minimum essential medium (MEM)
(Corning Inc., NY, USA) supplemented with 10% v/v heat-inactivated fetal bovine serum (FBS)
(Life Tech, Carlsbad, CA, USA) and 1% v/v penicillin/streptomycin at 37 °C under a
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humidified atmosphere of 5% CO2. The Cell Titer 96 Aqueous One Solution Cell Proliferation
Assay (Promega, Madison, WI, USA) was used. After seeding cells at a density of 1000
cells/well in 96-well plates in 200 µL complete medium, cells were allowed to attach overnight
before challenging with 0-20 μM of DMSO-dissolved or nanoencapsulated apigenin. After
incubation for 72 h, growth media were removed followed by adding 100 μL MEM containing
10%

v/v

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-

tetrazolium inner salt (MTS). Plates were incubated at 37 °C for 3 h and absorbance was
recorded at 490 nm. The growth inhibitory activity was expressed as the percentage with
respect to the absorbance of wells with untreated control cells. All experiments were performed
in at least three trials with four replicates per trail.
2.3.7 Cellular uptake studied with high-performance liquid chromatography (HPLC)
Cellular uptake of free and nanoencapsulated apigenin analyzed using HPLC was
modified from a method reported by Chen et al.25 Briefly, the nanodispersion prepared at 2
mg/mL apigenin was diluted to 5, 10 and 20 μM using the growth medium. Both HCT-116 and
HT-29 were seeded at 2 × 105 per well in 6-well plates and incubated overnight at 37 °C for
attachment. Cells were treated with 5, 10 and 20 μM of DMSO-dissolved or nanoencapsulated
apigenin for 24 h. After treatment, cells were washed twice with cold PBS, lysed, and harvested
by Radio immunoprecipitation assay (RIPA) buffer containing 1% v/v protease inhibitor
cocktail. The cell lysates were vortexed for 5 min at 4 °C and an aliquot of 5 μL lysates was
used to determine the protein concentration by Bradford assay, using bovine serum albumin as
the standard protein. The remaining lysates were mixed with 2 parts (v : v) of methanol and
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vortexed for 10 min in a cold room (4 °C), followed by 30 min ultrasonic treatment (Branson
1510 Ultrasonic Cleaner, MO, USA). Supernatant was collected after centrifugation (Sorvall
Legend Micro 21R Microcentrifuge, Thermo Fisher Scientific, Waltham, MA, USA) at 13,800
g for 10 min at 4 °C. The apigenin concentration in the cell lysates was analyzed using a
reserved phase HPLC system (1200 series, Agilent Technologies, Waldbronn, Germany) under
the detection wavelength of 340 nm. A binary solvent mixture of water with 4% formic acid
(solvent A) and acetonitrile (solvent B) at a gradient volume ratio from 88:12 to 50:50 was used
as the mobile phase. The concentration of apigenin was quantified with a calibration curve that
was established using standard solutions with 0-2.5 μg/mL apigenin dissolved in DMSO (y =
76.262x, R2 = 0.9997). The cellular uptake was then calculated as follows:
Uptake of AP (μg/mg) =

𝐶𝐴𝑃 (𝜇𝑔/𝑚𝐿)
𝐶𝑃 (𝑚𝑔/𝑚𝐿)

Where 𝐶𝐴𝑃 and 𝐶𝑃 represent concentrations of apigenin and protein in the cell lysates,
respectively.
2.3.8 Cell cycle analysis by flow cytometry
Analyses of cell-cycle distribution and apoptotic ratio were performed using flow
cytometry.26 Cells were prepared similarly to cellular uptake experiments by seeding at a
density of 2 × 105 per well in 6-well plates and were treated with DMSO-dissolved or
nanoencapsulated apigenin (5 μM, 10 μM, 20 μM) for 24 h. After which, cells were washed
twice with cold PBS and harvested with trypsinization. After centrifugation at 1,000 g for 5
min at 4 °C, the collected cell pellet was re-suspended in 60 μL cold PBS and fixed in 1mL icecold 70% ethanol. After being left to stand overnight, the permeabilized cells were collected
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by centrifugation (Sorvall Legend Micro 21R Microcentrifuge, Thermo Fisher Scientific,
Waltham, MA, USA) at 1,000 g for 10 min, 4 °C, and re-suspended in 1mL PBS containing 16
μg/mL propidium iodide (PI) and 30 μg/mL RNase A, and incubated at 37 °C for 60 min in the
dark. Fluorescence emitted from the PI-DNA complex was acquired at an excitation
wavelength of 488 nm using MACSQuant flow cytometer from Miltenyi Biotec Inc. (Bergisch
Gladbach, Germany). A total of 10,000 events were acquired for each sample. Results were
reported as the percentage of cells in each phase of cell cycle, and apoptotic ratios were reported
as relative folds to control cells. The analysis was performed independently in triplicates.
2.3.9 Statistical analysis
Data were expressed as mean ± SD (n ≥ 3). Results were analyzed by one-way ANOVA
using the IBM SPSS Statistics version 25.0 software (SPSS Inc., Chicago, IL, USA).
Significant difference were compared using Tukey’s test for multiple comparisons, and p <
0.05 was considered significantly different.

2.4 Results and discussion
2.4.1 Physicochemical characteristics of nanoencapsulated apigenin
When various concentrations of apigenin were studied, the encapsulation efficiency (EE)
was 93.44-98.38%, and the corresponding loading capacity (LC) was 57.19-195.78 mgapigenin/g-WPI (Figure 2-1A). These results were found to be higher than some previous
studies,14, 15, 27 and are important in drug delivery since low EE and LC may result in consuming
a larger amount of nanocarriers which may cause adverse effects.28 Zeta potential is the
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indicator of the surface charge of nanoparticles.28 Table 2-1 shows that WPI was negatively
charged after the pH-cycle treatment under the same encapsulation conditions. Zeta-potentials
of nanodispersions prepared with different initial apigenin concentrations were similar to the
pH-treated WPI, which suggested that encapsulation of apigenin with WPI has no significant
influence on the protein charge.
Particle size distributions of nanodispersions prepared with 0.6, 1.0, 1.5 and 2.0 mg/mL
apigenin were studied during 30-day ambient storage. With the elevated concentration of
apigenin, hydrodynamic diameters of nanodispersions increased from 180 nm to 240 nm,
which is possibly due to an increased loading capacity. The nanosized dimension enables the
obtained nanoparticles as effective carrier to deliver apigenin since most of the biological
processes occur at the nanoscale.29 Additionally, particle size distributions of all
nanodispersions maintained stable after 30-day storage (p > 0.05) (Figure 2-1B). The AFM
image (Figure 2-1C) showed near-spherical shape and uniform of nanoparticles, which is
consistent with the DLS results.
DSC was carried out to qualitatively study changes in the physical state of apigenin. As
shown in Figure 2-2A, the broad endothermic peak observed at around 100 °C of the pH-treated
WPI and nanocapsule sample was attributed to the evaporation of bound water.30 The sharp
endothermic peak at 366 °C represented the melting point of pristine apigenin, which was
absent in the thermogram of the nanocapsules. Therefore, apigenin existed in amorphism after
encapsulation in the protein matrix.
FTIR was applied to study the potential molecular interactions between apigenin and WPI.
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As shown in Figure 2-2B, the absorption peak at around 3278-3282 cm-1 of all samples is due
to the hydroxy stretching vibration (O-H) associated with intermolecular hydrogen bonds.31
Bands at the 1700-1500 cm-1 region correspond to the amide I (1700-1600 cm-1) and amide II
(1600-1500 cm-1) groups of proteins, attributing to the stretching vibrations of C-O groups and
the bending vibration of N-H groups, respectively.32 Hence, the peak of pristine apigenin at
1652 cm-1 shifting to 1631 cm-1 after encapsulation was possibly caused by the binding between
apigenin and amide I group of WPI. Besides, compared with the native WPI, there was a shift
of the absorbance peak from 1520 to 1532 cm-1 for the nanocapsules. This shift was indicative
of hydrophobic interactions, ascribing to structural changes of WPI after encapsulation of
apigenin using pH-cycle treatment, which was consistent with the peak in the pH-cycle treated
WPI. These results indicate non-covalent interactions between apigenin and protein molecules.
Protein profiles of unprocessed WPI, WPI after the pH-cycle treatment and the
nanodispersion prepared with 2 mg/mL apigenin and their pepsin hydrolysis products after
simulated gastric digestion as well as pancreatin hydrolysates after intestinal digestion were
analyzed using SDS-PAGE. As shown in Figure 2-3, compared with the unprocessed WPI, no
significant differences were detected after the pH-cycle treatment and encapsulation with
apigenin, indicating no hydrolysis after the pH-cycle treatment. After pepsin hydrolysis, high
molecular weight whey proteins were hydrolyzed significantly, while β-lactoglobulin was only
partially hydrolyzed, which shows resistance to peptic digestion of β-lactoglobulin.33 The
remaining β-lactoglobulin was completely hydrolyzed in the subsequent intestinal digestion.
These observations suggest that encapsulating apigenin with WPI can possibly enhance the
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solubility of apigenin in the gastric tract thus obtain a higher release in the intestine tract, which
may enhance the bioavailability of apigenin.
Taken together, the possible principle of encapsulating apigenin in WPI under the studied
conditions can be summarized in Figure 2-4. Apigenin is hardly dissolved in water at neutral
pH; however, it is deprotonated when pH increases to 13, which makes it negatively charged
and solubilized. Meanwhile, the globular whey proteins are unfolded, expose hydrophobic
amino acid residues to bind with apigenin and become loose under the alkaline pH.34 During
acidification to pH 7, apigenin loses charges and solubility due to protonation; the unfolded
whey proteins become refolded.35 The increased hydrophobicity of apigenin results in
aggregation together with bound proteins, which forms nanocapsules with multiple whey
proteins and a core enriched of apigenin.
2.4.2 In vitro anti-proliferative activity
Uncontrolled cell proliferation is known to be a hallmark of cancers. Thus, the growth
inhibitory activities of free (pre-dissolved in DMSO) and nanoencapsulated apigenin against
human colorectal cancer cells HCT-116 and HT-29 before and after simulated digestions were
evaluated.
As shown in Figure 2-5, both the free apigenin and encapsulated apigenin dose
dependently inhibited the proliferation of HCT-116 and HT-29. At 5 and 10 μM, apigenin
before and after nanoencapsulation showed similar anti-proliferative activities in both cell lines
(p > 0.05). However, at 20 μM, nanoencapsulated apigenin treatments exerted significantly
lower anti-proliferative effects, the viability of HCT-116 and HT-29 cells was reduced by 29.63%
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and 37.70%, respectively, after 72h incubation at 37 °C, while the administration of apigenin
pre-dissolved in DMSO, with respective viability reductions of 48.21% and 54.00% (p < 0.05).
These results may result from the protective effect of WPI which entrapped apigenin by binding
them with the hydrophobic residues in the protein molecules, and decreased the direct
interactions between apigenin and cells, with a less numbers of apigenin molecules that
exposed directly to cells.
In order to investigate the influence of digestion on the anti-proliferative activity of both
free and encapsulated apigenin, samples of 10 and 20 μM were further studied after the
simulated 2 h-gastric and 4 h-intestinal digestions. Figure 2-6 shows that both undigested and
digested samples dose-dependently inhibited HCT-116 and HT-29 after 72 h incubation at
37 °C. At 10 μM, no significant difference of the anti-proliferative activity was induced by the
digestion process for both free and nanoencapsulated apigenin; while at 20 μM, the treatment
of nanoencapsulated apigenin became significantly more cytotoxic after digestion (p < 0.05),
which was not found for free apigenin. WPI is completely hydrolyzed after the sequential
gastric and intestinal digestion (Figure 2-3), and the released apigenin can be dissolved by bile
surfactant micelle, which may be responsible for the enhanced inhibitory activity after
digestion. At 10 μM, apigenin was not enough to inhibit significant cell viability, thus the
digestion effect may become insignificant. Therefore, the simulated digestions did not
negatively affect the anti-proliferative activity of free apigenin (p > 0.05), but significantly
enhanced the ability of nanoencapsulated apigenin (p < 0.05).
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2.4.3 Cellular uptake of apigenin
Cellular uptake of apigenin pre-dissolved in DMSO (free) and nanoencapsulated in WPI
was assessed with HPLC after lysing cells. As presented in Figure 2-7A for HCT-116, after 24
h incubation, no significant difference between free apigenin and nanoencapsulated apigenin
treatments was observed at 5 and 10 μM. However, apigenin accumulated in HCT-116 reached
to 2.51 μg-apigenin/mg-protein for the 20 μM nanoencapsulated apigenin treatment, which was
significantly higher than the 0.37 μg-apigenin/mg-protein in cells that treated with 20 μM free
apigenin. For HT-29 cells (Figure 2-7B), cellular concentration of apigenin treated with 5 and
10 μM of free apigenin was not detectable, and 0.08 μg-apigenin/mg-protein was detected for
the 20 μM free apigenin treatment. For nanoencapsulated apigenin, the trend observed for HT29 cells was similar to that of HCT-116, reaching 2.75 μg-apigenin/mg-protein for the treatment
of 20 μM. It has been reported that particle dimension plays important roles in cell endocytosis,
as smaller particles can cross cellular membranes and permeate into cell cytoplasm more
easily.36 Nanoencapsulation prevent precipitation of apigenin in the cell culture medium, to
contribute to the enhanced cellular uptake when compared to free apigenin. The insignificant
difference of cellular uptake between free and encapsulated apigenin at 5 and 10 μM (Figure
2-7) agrees with no difference in cell proliferation (Figure 2-5). No correlation between the
cellular uptake and cytotoxicity at 20 μM is probably due to the different mechanisms among
these measurements to indicate anticancer activity.
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2.4.4 Effects of apigenin on cell cycle distribution and apoptotic ratio
To identify the possible mechanisms involved in cell growth inhibited by apigenin, cell
cycle progression and pre-apoptotic ratio were evaluated using flow cytometry after free and
nanoencapsulated apigenin treatments. The apoptotic ratio was calculated as relative folds that
of control cells. As shown in Figure 2-8A, both free and nanoencapsulated apigenin dosedependently induced apoptosis of HCT-116 after 24 h treatment. Incubation with 20 μM of free
apigenin resulted in 2.77 folds of apoptotic cells compared with control cells, while 20 μM of
nanoencapsulated apigenin induced 3.33 folds of apoptotic cells. Similarly, administration of
20 μM nanoencapsulated apigenin induced a much higher apoptotic ratio of HT-29 cells, with
3.10 folds that of control cells, while free apigenin at the same dosage resulted in 2.16 folds of
apoptosis (Figure 2-9A). The enhanced cell apoptotic ratio is consistent with the cellular uptake
results (Figure 2-7). Correspondingly, the percentage of cells distributed in the cell cycle phase
decreased as the treatments caused significant apoptotic cells (Figure 2-8B, C; Figure 2-9B, C).
These results indicate that apigenin affected cell proliferation, at least in part, by inducing cell
apoptosis rather than arresting cell cycle progression, and nanoencapsulation potentially
enhanced the apoptosis induction.

2.5 Conclusions
In summary, the current study demonstrated a low-cost, low-energy, and organic solventfree process to use whey protein isolate to fabricate a nanodelivery system of apigenin. With
0.6-2.0 mg/mL apigenin, the studied conditions resulted in high encapsulation efficiencies of
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93.44-98.38% and the corresponding loading capacity of 57.19-195.78 mg-apigenin/g-WPI.
The nanodispersions had hydrodynamic diameters of 180-240 nm and exhibited good storage
stability. The improved dispersibility and small dimension of nanoencapsulated apigenin
enhanced the cellular uptake of apigenin in human colon cancer cells of HCT-116 and HT-29.
As a result, cell apoptosis was significantly enhanced by administration of nanodispersion,
which partially contributed to the growth inhibitory activity of apigenin. The present study
suggests the potential of the nanodelivered apigenin in the development of functional beverages
for disease prevention. However, further studies remain to be conducted to elucidate the effect
against various cancer cells in vitro and in vivo.
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Appendix
Table 2-1. Zeta-potential of pH 7.0 nanodispersions with 1% w/v and different amount of
apigenin after the pH-cycle treatment
Initial apigenin con. (mg/mL)
Zeta-potential (mV)
0 (pH-treated WPI)
-20.43 ± 1.41 a
0.6
-20.10 ± 1.57 a
1.0
-20.50 ± 1.44 a
1.5
-21.53 ± 1.52 a
2.0
-21.60 ± 1.43 a
Numbers are mean ± standard deviation (n = 3). The same letters indicate no significant
difference (p > 0.05).
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Figure 2-1. (A) Encapsulation efficiency and loading capacity as affected by the amount of
apigenin (AP); (B) Particle size distributions of nanodispersions prepared with (1) 0.6, (2) 1.0,
(3) 1.5, or (4) 2.0 mg/mL AP during 30-day storage at 21 °C; (C) AFM image of nanodispersion
prepared with 2.0 mg/mL AP in height channel (top) and 3-dimensional view (bottom);
.
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Figure 2-2. (A) DSC thermograms of pristine AP, pH-treated WPI and powder lyophilized
from nanodispersion sample with 2.0 mg/mL AP; (B) FTIR spectra of (a) pristine AP, (b)
unprocessed WPI, (c) pH-treated WPI and (d) powder freeze-dried from nanodispersion with
2.0 mg/mL AP.

104

Figure 2-3. Electrophoretic profile of (1) Native WPI, (2) pH-treated WPI, (3) nanodispersion
with 2 mg/mL AP; (4) native WPI, (5) pH-treated WPI, and (6) nanodispersion after simulated
gastric digestion; (7) native WPI, (8) pH-treated WPI, and (9) nanodispersion after simulated
gastric and intestinal digestions. Lane Mw represents the molecular weight marker.
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Figure 2-4. Proposed structural changes leading to nanoencapsulation of apigenin in WPI
during the pH-cycle.
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Figure 2-5. Anti-proliferative activity of 0, 5, 10, and 20 μM of free (pre-dissolved in DMSO)
apigenin (AP) and nanoencapsulated AP (En-AP) against (A) HCT-116 and (B) HT-29 colon
cancer cells after 72-h incubation at 37 °C. Error bars are standard deviations (n ≥ 3).
Treatments labeled with p < 0.05 represent a significant difference between each other.
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Figure 2-6. Anti-proliferative activity of 0, 10, and 20 μM of (1) free (pre-dissolved in DMSO)
apigenin (AP) and (2) nanoencapsulated AP (En-AP) against (A) HCT-116 and (B) HT-29
colon cancer cells before and after in vitro digestions after 72-h incubation at 37 °C. Error bars
are standard deviations (n ≥ 3). Treatments labeled with p < 0.05 represent a significant
difference between each other.
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Figure 2-7. Cellular uptake of 5, 10, and 20 μM of free (pre-dissolved in DMSO) apigenin (AP)
and nanoencapsulated AP (En-AP) in (A) HCT-116 and (B) HT-29 colon cancer cells after 24h incubation at 37 °C. Error bars are standard deviations (n = 3). Different letters above columns
indicate significant differences (p < 0.05).
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Figure 2-8. Flow cytometry analysis of relative apoptotic ratio (A) and the percentage of (B,
C) cell cycle distribution of HCT-116 cell line treated by 0, 5, 10, and 20 μM of free (predissolved in DMSO) apigenin (AP) and nanoencapsulated AP (En-AP) for 24 h at 37 °C.
Relative apoptotic ratio was calculated with reference to control cells without AP treatment.
Error bars are standard deviations (n = 3). Different letters above columns indicate significant
differences (p < 0.05).
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Figure 2-9. Flow cytometry analysis of relative apoptotic ratio (A) and the percentage of (B,
C) cell cycle distribution of HT-29 cell line treated by 0, 5, 10, and 20 μM of free (pre-dissolved
in DMSO) apigenin (AP) and nanoencapsulated AP (En-AP) for 24 h at 37 °C. Relative
apoptotic ratio was calculated with reference to control cells without AP treatment. Error bars
are standard deviations (n = 3). Different letters above columns indicate significant differences
(p < 0.05)
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Chapter 3. Oral bioavailability and in vivo anti-colorectal cancer effects
of apigenin nanoencapsulated with whey protein isolate

112

3.1 Abstract
Apigenin is a food-sourced lipophilic polyphenol with anti-cancer activities. In chapter 2,
stable aqueous dispersions were prepared after mixing apigenin and whey protein isolate (WPI)
at alkaline pH followed by titrating to pH 7.0. The present objective was to characterize
bioavailability of nanoencapsulated apigenin and in vivo anti-colorectal cancer activities. Two
groups of C57BL/6J mice were orally administered with 50 mg/kg-mice-body-mass of free or
nanoencapsulated apigenin. Blood and colon mucosa were collected at 0, ~1, ~6, and ~24 hr
after oral gavage and euthanization of mice. After HPLC analysis, apigenin concentration in
serum and colon mucosa of mice treated with nanoencapsulated apigenin was found to be 1.39
and 1.41 times that of free apigenin, respectively, implying the absorption of apigenin was
enhanced by the nanodelivery system. Additionally, four groups of 12 ApcMin+ mice were each
administered with vehicle (0.5% w/v methylcellulose), 50 mg/kg-mice-body-weight free or
nanoencapsulated apigenin, and a solution with WPI amount equivalent to the apigenin
nanodispersion by oral gavage for 21 times every other day to investigate the anticancer
efficacy of apigenin. The entire intestinal tract was removed to evaluate the tumorigenesis and
apoptosis after euthanization. However, neither free apigenin nor nanoencapsulated apigenin
significantly affected polyps numbers (p > 0.05). Terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) assay showed no significant difference of apoptosis in mouse
intestine within different treatments. Tumors isolated from colonic tissues were analyzed for
COX-2, β-catenin, c-myc and cyclin D1, and no significant difference of relative expression
was observed between treatments. Effects of apigenin in inflammatory response in vivo were
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studied by analyzing cytokines (TNF-α, IL-1β and IL-6) both in the serum and colon mucosa.
None of these cytokines was significantly affected by different treatments. The current study
understanding the in vivo fate of nanoencapsulated apigenin may assist the advancement and
formulation of functional foods incorporated with phytochemicals.

Keywords: apigenin, nanoencapsulation, in vivo, bioavailability, anticancer activity
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3.2 Introduction
Colorectal cancer (CRC) has continued to be one of the most commonly diagnosed
cancers in the world. In 2018, over 881,000 deaths were estimated among the total 1.8 million
new CRC cases. The alarming mortality has made CRC a big threat to human health as it has
been the second most prevalent cause of the cancer-related death in the overall population.1
While only about 5-10% of CRC cases are hereditary, approximately 90% CRC cases are
sporadic, involving genetic mutations that lead to the conversions of normal functional
epithelial cells to adenocarcinoma and carcinoma.2, 3 In addition to genetic alterations, CRC is
highly influenced by poor lifestyle, such as low physical exercise, obesity, cigarette smoking,
alcohol abuse, and overconsumption of fat or red meat.4,

5

The long-standing chronic

inflammatory bowel diseases including ulcerative colitis and Crohn’s disease also account for
the increasing risk of CRC.6, 7 Since the current therapeutic treatments involving a combination
of surgery, radiation, and chemotherapy still have not completely controlled the incidence and
outcome of CRC and have severe adverse effects, many researchers have turned to dietary
factors to seek potential alternative therapeutic interventions.8-10
Mounting evidence have suggested an inverse association of a high intake of fruits and
vegetables with the reduced risk of developing CRC, on account of the high content of dietary
fiber and polyphenols.11 Dietary polyphenols are the most important bioactive phytochemicals,
occurring as the secondary metabolites of plants, which help plants to adapt to their
environment and protect them against environmental stimulators and stress such as reactive
oxygen species, photosynthetic stress and others.12, 13 Apigenin (4’,5,7-trihydroxyflavone), a
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compound found most commonly in parsley, onion, orange, paper mulberry, and chamomile,14,
15

has been studied extensively for possible cancer preventive effects.8,

16, 17

Potential

mechanisms are recognized by targeting diverse molecules and kinase pathways, including
promoting cell cycle arrest18 and apoptosis,19, 20 inhibition of mutagenesis,21 and suppression
of signal transduction.22, 23. However, studies regarding in vivo inhibitory effects of apigenin
against CRC are limited and inconclusive. Free apigenin has shown potential anti-tumorigenic
activity by decreasing polyps numbers and tumor load in Min/+ mice,24 whereas in another
study, apigenin failed to inhibit adenoma formation in the same mice model.25
In order to exert therapeutic efficacy, phenolic compounds must be absorbed by human
body after ingestion, and have to reach a considerable level that is high enough to exert health
beneficial effects in the blood stream or to the target organ site.26 Many lipophilic polyphenols
are questionable in applications due to their poor bioavailability that refers to the proportion of
an ingested bioactive component that is absorbed into systemic circulation and becomes
available at the required site.27 Apigenin is reported as a quite hydrophobic drug with very low
water solubility and poor bioavailability.15, 28 In Chapter 2, a pH-cycle method was successfully
applied to nanoencapsulate apigenin with whey protein isolate (WPI) to improve the
dispersibility. The obtained stable aqueous dispersions had promising in vitro anticancer
activities against human CRC cells, HCT-116 and HT-29. However, to date, the in vivo antiCRC efficacy of nanodelivered apigenin remains unexamined. To this end, the aim of this study
was to evaluate the oral bioavailability of nanoencapsulated apigenin and the in vivo effects on
intestinal tumorigenesis in ApcMin+ mouse, a model carrying heritable mutant adenomatous
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polyposis coli (APC) gene and is frequently employed to study colorectal carcinogenesis in the
preclinical selection of chemopreventive agents for further development.29, 30

3.3 Materials and methods
3.3.1 Materials
Apigenin (>98%) was purchased from Indofine Chemical Co. Inc (Hillsborough, NJ,
USA). WPI was purchased from Hilmar Ingredients (Hilmar, CA, USA). Primary antibodies
(β-catenin 51067-2-AP, cyclin D1 60186-1-Ig, COX-2 66351-1-Ig, c-myc 10828-1-AP and βactin 66009-1-Ig) were purchased from Proteintech (Rosemont, IL, USA). Secondary
antibodies (goat anti-mouse and goat anti-rabbit) were purchased from Li-Cor Biosciences Inc.
(Lincoln, NE, USA). ELISA kits (mouse TNF-α, IL-6 and IL-1β) were purchased from
BioLegend (San Diego, CA, USA). All other chemicals were obtained from Thermo Fisher
Scientific (Pittsburgh, PA, USA) unless otherwise stated.
3.3.2 Preparation of nanoencapsulated apigenin
Nanoencapsulated apigenin was prepared similarly as described in Chapter 2. Briefly, 4%
w/v WPI was hydrated in deionized water overnight at 4 °C, followed by mixing with 8 mg/mL
apigenin and adjusting pH to 13.0 using 2.0 M KOH solution. The mixture was adjusted to pH
10.0 after stirring for 5 min at 21 °C. The sample was stirred for another 30 min before titration
to pH 7.0 with 1.0 M HCl. After centrifugation at 10,000 g for 10 min (Sorvall LYNX 6000
Centrifuge, Thermo Fisher Scientific, Waltham, MA, USA), the supernatant was collected as
the nanoencapsulated apigenin.
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3.3.3 In vivo bioavailability of nanodelivered apigenin
3.3.3.1 Animals
All Animal experiments were carried out under the approval of the University of
Tennessee Animal Care and Use Committee (Protocol #2369-0615) and were in compliance
with the National Institute of Health guidelines for the care and use of laboratory animals.
Thirty C57BL/6J mice (strain for ApcMin+ mice) of 7-week old (Jackson Laboratories,
Harbor, ME, USA), including both males and females, were randomly housed in standard
mouse cages (23 ± 2 °C, 30-70% relative humidity, 12 h light and 12 h dark cycle). Mice were
provided with rodent diet and water ad libitum. Mice were randomly separated into two groups
after one week acclimatization, and fed with free apigenin that was suspended in 0.5% w/v
methylcellulose (vehicle) or nanoencapsulated apigenin in accordance with the dosage of 50
mg/kg apigenin by oral gavage, respectively. After oral administration, mice were euthanized
by CO2 inhalation at 0, ~1, ~6, and ~24 hr, blood was then obtained by cardiac puncture and
colon mucosa was collected. Blood samples were centrifuged at 900 g for 15 min (Sorvall
Legend Micro 21R Microcentrifuge, Thermo Fisher Scientific, Waltham, MA, USA), and the
serum was separated, collected, and stored at -80 °C until analysis.
3.3.3.2 Measurement of apigenin from mouse colon mucosa and serum
Fifty microliters of the serum sample were mixed with 100 μL methanol to extract
apigenin. The mixture was vortexed for 3 min at 4 °C and was then ultrasonically treated
(Branson 1510 Ultrasonic Cleaner, MO, USA) for 20 min. The supernatant was obtained after
centrifugation at 13,800 g for 10 min (Sorvall Legend Micro 21R Microcentrifuge, Thermo
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Fisher Scientific, Waltham, MA, USA).
To extract apigenin from mice colon, colon mucosa was rinsed with PBS, mixed with 3
mL clean PBS and homogenized at 8,000 rpm twice for 30s each (Kinematica Polytron PT
10/35 GT Homogenizer, Fisher Scientific, Hampton, NH, USA). After centrifugation for 10
min at 1,900 g (Sorvall Legend Micro 21R Microcentrifuge, Thermo Fisher Scientific,
Waltham, MA, USA), the supernatant was processed under the same procedure as mice serum
to extract apigenin. One milliliter of DMSO was added into the remainder mucosa precipitate
to extract apigenin from the precipitation by vortexing at the ambient temperature for 1 h and
the supernatant was collected after centrifugation for 10 min at 14,000 g (Sorvall Legend Micro
21R Microcentrifuge, Thermo Fisher Scientific, Waltham, MA, USA). Apigenin distributed in
both mice serum and colon mucosa was quantified using HPLC analysis as in Chapter 2.
3.3.4 In vivo anticancer activities
3.3.4.1 Animal studies
Procedures in animal studies followed the National Institute of Health guidelines and were
approved by the University of Tennessee Animal Care and Use Committee (Protocol #23690615). Forty-eight ApcMin+ mice of 8-week age (Jackson Laboratories, Harbor, ME, USA),
including both males and females, were randomly assigned into four treatment groups of 12
mice each with 6 males and 6 females. Mice were administered by oral gavage with vehicle
(0.5% w/v methylcellulose), 50 mg/kg of free apigenin suspended in 0.5% w/v methylcellulose,
encapsulated apigenin equivalent to 50 mg/kg apigenin, and WPI solution treated with the same
pH-cycle at an amount equivalent to the WPI amount in the apigenin nanodispersion for 21
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times every other day. At the termination of the study at around ~100 days of age, mice were
euthanized by CO2 inhalation, blood was collected by cardiac puncture, and blood serum was
collected after centrifugation (Sorvall Legend Micro 21R Microcentrifuge, Thermo Fisher
Scientific, Waltham, MA, USA) at 900 g for 15 min for cytokine analysis. The entire intestinal
tract was excised, flushed with cold PBS, and opened longitudinally. The number, size and
location of polyps in the small intestine were recorded from proximal to distal parts

30

. The

middle parts were swiss rolled and fixed in 4% neutral buffered formalin for tissue apoptosis
study. The remainder tissues were frozen immediately in liquid nitrogen and stored at -80 °C
for further analysis.
3.3.4.2 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay
The TUNEL assay was used to study apoptosis in the middle part of small intestine.
Tumors embedded in paraffin were first deparaffinized, and the apoptotic tissues were stained
by green fluorescence using a DeadEnd™ Fluorometric TUNEL System (Promega, Madison,
WI, USA) based on manufacturer’s protocol. For each sample, 10 fields with 10×
magnification were chosen randomly, and ImageJ software (NIH, Bethesda, MD, USA) was
used to quantify the green fluorescence intensity.
3.3.4.3 Protein extraction and Western blotting analysis
To further characterize the mechanisms involved, lysates of colon tumors and normal
colonic tissues from different treatment groups were subjected to western blot to examine the
molecular expression of different tumor markers including cyclooxygenase-2 (COX-2), βcatenin, c-myc and cyclin D1 (ProteinTech, Chicago, IL, USA) that related to proliferation and
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apoptosis.31-34 Tumors were isolated from colonic tissues. The total cellular lysates of both
neoplastic tumors and normal tissues were prepared according to a method reported previously
with some modifications

30

. Specifically, separated tumors and normal colonic mucosa

counterparts were homogenized at 3,400 rpm (HT Mini Microtube Homogenizer, OPS
Diagnostics, Lebanon, NJ, USA) for 1 min at 4 °C after addition of RIPA buffer containing 1%
v/v protease inhibitor cocktail. After centrifugation (14,000 g, 4 °C, 10 min) twice (Sorvall
Legend Micro 21R Microcentrifuge, Thermo Fisher Scientific, Waltham, MA, USA), the
supernatants were combined, a proportion of the sample was used to determine protein
concentration using the Bradford assay (Thermo Scientific Inc., Pittsburgh, PA, USA), and the
rest of the sample was mixed with an equal volume of Laemmli Buffer with 5% v/v βmercaptoethanol and boiled at 100 °C for 5 min. Western blotting analysis was conducted
according to a previous protocol.35 Equal amounts of protein (25 μg) were loaded to 4-20%
Mini-Protean TGX gels (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The gel
electrophoresis was run at 200V for 35 min at ambient temperature (21 °C). After which, the
separated proteins were transferred to a PVDF membrane (GE Healthcare Life Sciences,
Pittsburgh PA, USA) using Trans-Blot Turbo Transfer System (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). The membrane was then blocked with 5% non-fat dry milk in trisbuffered saline containing 0.1% Tween 20 (TBST) for 1 h at 21 °C, followed by washing with
TBST three times for 5min each time. After incubation with primary antibodies against COX2, β-catenin, and c-myc at dilution of 1:1000 in 1% non-fat dry milk of TBST, cyclin D1 and
GAPDH at dilution of 1:5000 of overnight at 4 °C, membranes were washed three time for 10
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min with TBST, and incubated for 1.5 h at room temperature with anti-rabbit or anti-mouse
secondary antibody at 1:5000 dilution. Following washing with TBST three time for 10 min,
expressions of proteins were imaged using a C-Digit blot scanner (Li-Cor Biosciences, Lincoln,
NE, USA) with Bio-Rad ClarityTM Western ECL Substrate (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). The intensity of bands was quantified using ImageJ software (NIH,
Bethesda, MD, USA).
3.3.4.4 Inflammatory cytokines assays
The blood serum as well as colonic extracts were used to measure the expression of proinflammatory cytokines (TNF-α, IL-6, IL-1β) using ELISA kits according to manufacturer’s
instructions (BioLegend, San Diego, CA, USA). To extract cytokines from colon mucosa, 50
mg tissues were homogenized (TissueLyser II, QIAGEN, Hilden, Germany) for 6 min at a
frequency of 30/second by mixing with 1 mL extracting reagent (0.05 mL 1 M Tris-HCl, 0.03
mL 5 M NaCl solution, 0.01 mL Tween 20, 0.91 mL deionized water) supplemented with 0.5%
v/v protease inhibitor cocktail. After centrifugation for 15 min at 20,000 g, 4 °C twice (Sorvall
Legend Micro 21R Microcentrifuge, Thermo Fisher Scientific, Waltham, MA, USA), 5 μL of
the supernatant was used to measure protein concentration based on the Bradford assay, and
the rest of the supernatant was analyzed for cytokine levels. Cytokines were expressed as pg
of cytokines per milliliter of serum and pg of cytokines per microgram protein in colonic
extracts. All standards and samples were measured in two independent replicates.
3.3.5 Statistical analysis
Data were expressed as mean ± SD (n ≥ 3). Results were analyzed by one-way ANOVA
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with application of the IBM SPSS Statistics version 25.0 software (SPSS Inc., Chicago, IL,
USA). Significant difference among results were compared using Tukey’s test multiple
comparisons, and p < 0.05 was considered as significant difference. Graphpad Prism 7 software
(GraphPad Software, Inc., La Jolla, USA) was used for statistical analyses for tumorigenesis
evaluation.

3.4 Results and discussion
3.4.1 In vivo bioavailability of apigenin influenced by nanoencapsulation
The apigenin concentration in mice serum and colon mucosa is shown in Figure 3-1. It
was found that the bioavailability of apigenin in mice treated with nanoencapsulated apigenin
was always higher than that of mice treated with free apigenin at the same dosage (Figure 31A).One hour after gavage, the maximum apigenin concentration in the serum was observed
for both encapsulated and free apigenin, which was 28.70 and 19.05 μM, respectively. The oral
bioavailability of nanoencapsulated apigenin, determined from the area under curve based on
the determined time points, was found to be 1.39 times that of free apigenin. Moreover, the
concentration of apigenin in mouse colon mucosa of the nanodispersion treatment was 1.41
folds that of free apigenin (Figure 3-1B). These findings imply that the absorption of apigenin
was enhanced by the nanodelivery system.
However, the apigenin concentration rapidly declined in both mice serum and colon
mucosa 6 hours after gavage, and became undetectable after 24 hours. As noted in Chapter 2,
WPI is hydrolyzed in the gastrointestinal environment, especially in the intestinal tract, which

123

may account for the quick elimination of the absorbed apigenin, similarly to free apigenin. On
the other hand, although some previous studies showed higher enhancement of apigenin
bioavailability after encapsulation with poloxamer using liquid antisolvent precipitation
technique or loading into mixed micelles made from Soluplus and Pluronic F127 with ethanol
thin-film hydration,36, 37 it is worth to mention that the usage of organic solvent and high amount
of surfactant impede the further application of these nanocapsules in food systems.
3.4.2 In vivo anticancer studies
3.4.2.1 Effects of apigenin on intestinal tumorigenesis in ApcMin/+ mice
ApcMin/+ mice were oral administrated with free or nanoencapsulated apigenin under the
same dosage of 50 mg/kg-body weight, to assess the anti-tumorigenesis activity of apigenin.
Both number and size of polyps in different intestinal sections and colon were recorded. As
shown in Figure 3-2A, B, ApcMin/+ mouse polyps were mostly located in the medial and distal
sections of the small intestine, with the primary size ranging from 1-2 mm. Only very few,
mostly large, lesions were located in the colon. The total polyps number was further compared
within different groups. As shown in Figure 3-2 C, compared with control groups, neither free
apigenin nor nanoencapsulated apigenin significantly affected the number of polyps (p > 0.05).
A previous study also reported that apigenin failed to inhibit adenoma formation in the Min
mice model, but reduced the aberrant crypt foci formation (ACF) which leads to early
preneoplastic lesions and development of adenoma and polyps.25 Therefore, the antitumorigenesis activity of apigenin may vary greatly over different stages of CRC development.
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3.4.2.2 Effects of apigenin on apoptosis in intestinal tissue
The intestinal tumor development in ApcMin/+ mice was evaluated for the level of apoptosis
by the TUNEL staining of sections from middle small intestine Swiss rolls. Apoptotic tissues
were defined as green fluorescence while the DAPI-stained nuclei were blue (Figure 3-3A).
Green intensity from 10 randomly selected fields with each section was calculated to determine
the pro-apoptotic effects of apigenin. As shown in Figure 3-3B, the quantified green
fluorescence showed a slightly lower intensity in mice tissues after apigenin treatments,
however, the differences of apoptosis were not statistically different among four treatment
groups.
Expressions of COX-2, β-catenin, c-myc, and cyclin D1 were analyzed to further address
the effects of apigenin on intestinal tumorigenesis in molecular level. Figure 3-4A presents
higher expressions of all the studied proteins in tumors compared with their normal colonic
mucosa counterparts as expected. Since only one mouse in the WPI treatment group developed
tumor in colon and was not statistically meaningful, relative expression of each protein was
quantified and compared between vehicle, free apigenin and nanoencapsulated apigenin
treatment groups. As shown in Figure 3-4B, both free and encapsulated apigenin slightly
suppressed the expressions of c-myc and β-catenin in tumors, however, the difference was not
significant (p > 0.05). On the other hand, apigenin treatments failed to inhibit the expression
of cyclin D1, which may suggest an inactive role of apigenin in regulating cell cycle.
Nevertheless, relative expressions of all the above tumor markers showed no significant
difference between vehicle and apigenin (both free and nanoencapsulated) treatment groups
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(p > 0.05), which is consistent with results obtained in the TUNEL assay (Figure 3-3). More
comprehensive studies involving other proteins and signaling pathways are to be conducted to
elucidate the potential roles of apigenin on cell proliferation, apoptosis, and tumor progressions.
3.4.2.3 Effects of apigenin on expression of inflammatory cytokines
Chronic inflammation plays a crucial role in regulating immune responses relevant to the
initiation or promotion of CRC development.38 Cytokines are essential mediators that
contribute to modulating immune and inflammatory responses during infections and tissue
injuries; cytokines also promote tumor progression by inhibiting cell apoptosis at the site of
inflammation.39, 40 Hence, in this study, levels of the pro-inflammatory cytokines TNF-α, IL1β and IL-6, both in mice serum and colonic extracts were analyzed using ELISA to determine
the effects of apigenin in inflammatory response in vivo. As presented in Figure 3-5B, none of
the detected cytokines was significantly affected by apigenin (both free and encapsulated)
treatments in colonic extracts and serum with respect to vehicle group (p > 0.05).

In Chapter 2, nanoencapsulation enhanced cellular uptake of apigenin and the antiproliferative activity against human colon cancer cells was also enhanced after simulated
digestions. Nanoencapsulation enhanced the oral bioavailability of apigenin in mice serum
(Figure 3-1A), leading to possibly a smaller amount in the colon. Although apigenin
concentration in the colon mucosa was also enhanced after nanoencapsulation (Figure 3-1B),
this concentration may not be enough to inhibit tumor growth.
Many studies reported contrary results of dietary polyphenols in vitro and in vivo.41, 42
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These disagreements may result from many factors. One reason for this discrepancy is that
concentrations used in most in vitro and in vivo studies are different , which makes it difficult
to link the physiological relevance with in vitro studies.43 Although the concentration of
absorbed apigenin in mice serum (Figure 3-1A) in the current study is relevant to that in the
cell culture studies in Chapter 2, the relevance of apigenin concentration in colon mucosa
(Figure 3-1B) remained unknown. In addition, the rapid elimination and metabolism of
apigenin (Figure 3-1) may be responsible for the ineffectiveness of apigenin in vivo. Besides,
once polyphenols are absorbed into the systemic circulation, they are capable of binding with
soluble proteins in the blood and tissues. As the “free drug” hypothesis suggests, only
compounds unbound to plasma proteins exert biological activity.44 Apigenin has been reported
to bind strongly to human serum albumin,45 which on the other hand, may explain the nonsignificant anti-cancer activity in vivo although the absorbed concentration in the serum has
reached to the cell culture dosage. Moreover, despite that apigenin was easily to access colon,
the accumulated apigenin in colon mucosa may act on the whole inner wall of colon, instead
of targeting and specifically interacting with colonic polyps and tumors, which may largely
attenuate the biological activities of apigenin.
Additionally, it cannot be discarded that derivatives of bioactive compounds may be
formed during experimental incubation times in vitro, which might not be taking place in vivo
or differ from derived metabolites that are produced by gut microbiota in vivo, and the activity
of these derived products remains unknown. Apart from these, although Min mice are
frequently used to study colon carcinogenesis, the small intestine is the place of most adenomas

127

in the Min mice, with none or only a few adenomas found in the colon; thus the adenomas in
the Min mouse study are developed in a microenvironment different from that of the colon,25,
46

which makes it impossible for apigenin that accumulated in colon mucosa to affect the

adenomas in the small intestine.
Lastly, the different location of the APC mutation in the Min mice (chromosome 18) and
that in human colon cancer cell lines (for example, chromosome 5q21 for HT-29) may be
responsible for the discrepancy between the human colon cancer study and the Min mice
experiments.46 Also, the complicated environment in vivo including gut microbiota and other
neighbor cells plays possible roles on the anticancer activities of compounds. Therefore, under
the proposed study conditions, there was insufficient data to make a conclusion on the in vivo
fate of nanoencapsulated apigenin. Further studies involving different dosages, other mouse
models that better simulate human colon tumors as well as different cancer types are needed to
better assess the potential in vivo efficacy of the studied nanodelivery system of apigenin.

3.5 Conclusions
Nanoencapsulation of apigenin with whey protein isolate enhanced the oral bioavailability
of apigenin and absorption in colon mucosa. However, neither the free apigenin nor the
encapsulated apigenin positively suppressed colon carcinogenesis in vivo in the current animal
model, as analyzed based on polyps numbers, tissue apoptosis, tumor marker expressions, and
inflammatory cytokines. The potential in vivo effectiveness of apigenin on cancer development
must be further studied.
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Appendix

Figure 3-1. Apigenin concentration of mice after oral gavage with 50 mg/kg-body weight of
free apigenin (AP) and encapsulated AP (En-AP) in the serum (A) and colon mucosa (B). Error
bars are standard deviations (n ≥ 3).
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Figure 3-2. Tumorigenesis evaluation of mice treated with vehicle (0.5% w/v methylcellulose),
pH-treated WPI, 50 mg/kg-mice-body-mass free apigenin (AP) or nanoencapsulated AP (EnAP): Location (A), size distribution (B) and total number (C) of polyps in the small intestine
of mice.
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Figure 3-3. TUNEL assay of apoptotic cells in colon mucosa within different treatment groups:
(A) Green staining represented apoptotic cells (10× magnifications); (B) Green intensity
calculated from 10 randomly selected fields with each section. Error bars represent standard
deviations.
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Figure 3-4. Western blot of tumor markers (COX-2, β-catenin, c-myc, cyclin D1). “T” and “C”
represent tumor and normal colonic tissue, respectively, in (A). Relative expression is
calculated based on standard marker of β-actin (B). Error bars are standard deviations (n ≥ 3).
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Figure 3-5. Effects of apigenin over inflammatory response in vivo as analyzed for cytokines
(TNF-α, IL-1β, IL-6) in mice serum (A) and colon mucosa (B). Error bars are standard
deviations (n ≥ 3).
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Chapter 4. Synergistic anti-inflammatory activity of free and coencapsulated apigenin and curcumin in lipopolysaccharide-stimulated
RAW 264.7 macrophages
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4.1 Abstract
Inflammation in the chronic state is involved in initiation and promotion of many diseases
including cancers. Dietary polyphenols have been widely accepted as potent anti-inflammatory
agents. Combinations of two or more polyphenols potentially achieve better biological benefits
with lower toxicity and side effects. The objective of this work was to investigate the potential
synergistic anti-inflammatory activities of two important dietary compounds, apigenin and
curcumin, in physical combinations, and the enhanced synergism by co-encapsulation. Nontoxic concentrations of apigenin, curcumin, and their physical mixtures as well as their
coencapsulated dispersions were studied in lipopolysaccharide (LPS)-stimulated RAW 264.7
macrophages. For physical mixtures of unencapsulated polyphenols, a higher mass proportion
of curcumin produced stronger inhibitory effects on nitric oxide (NO) production, and the
synergistic interactions between apigenin and curcumin were enhanced by co-encapsulation
based on the calculated combination index (CI). Western blot analysis revealed that the
synergistic inhibition of NO was at least partially concomitant with a reduction in the protein
expression of LPS-induced nitric oxide synthase (iNOS). To better understand the synergistic
anti-inflammatory activities of apigenin and curcumin as well as their combinations, proinflammatory cytokines of IL-6 and TNF-α were further measured by ELISA. Since oxidative
stress caused by the overproduction of intracellular reactive oxygen species (ROS) has been
implicated in chronic inflammation and many diseases, ROS production was also analyzed by
fluorescence microscopy and spectrophotometry. Similar synergistic activities of physical
mixtures and coencapsulated dispersions were also found in mediating the production of
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cytokines and ROS. Overall, these results demonstrated that apigenin and curcumin in specific
combinations exerted synergistic effects in inhibiting LPS-induced inflammation in RAW
264.7 cells, and the co-encapsulation enhanced the synergistic activity.

Keywords: apigenin, curcumin, co-encapsulation, synergistic interaction, anti-inflammatory
activity
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4.2 Introduction
Inflammation is the defensive response of immune system to traumatic injuries or
pathogenic infections, which cause disruptions of tissue homeostasis.1 It is activated via the
indentification of exogenous pathogen-associated molecular patterns (PAMPs) or damageassociated molecular patterns (DAMPs) by pathogen-recognition receptors (PRRs).2 Acute
inflammation is beneficial; however, the long-term chronic inflammation is always involved in
progression of several chronic diseases, including cancers, diabetes, obesity and
neurodegenerative disorders.3, 4 Chronic inflammation has been proposed to be oncogenic by
inducing genomic instability, promoting cell growth, inhibiting cell apoptosis, and also
stimulating angiogenesis.5 Therefore, controlling inflammation is an important strategy to
prevent and treat cancers.
Inflammatory process is highly complicated, which is orchestrated by various immune
cells through induction of a complex set of inflammatory mediators, such as cytokines,
chemokines, pro-inflammatory transcription factors and pro-inflammatory enzymes.6,

7

Macrophages, as one of the primary immune cells, perform a critical role in initiating and
developing inflammatory responses. Upon the stimulation by lipopolysaccharide (LPS) which
is a major component of the outer membrane of Gram-negative bacteria,8 macrophages are
activated and undergo a sequential release of diverse inflammatory factors including NO, IL-6
and TNF-α.4 Nitric oxide (NO), as a representative pro-inflammatory mediator, is regulated by
inducible nitric oxide synthase (iNOS). Pro-inflammatory cytokines, such as interleukin-6 (IL6) and tumor necrosis factor-α (TNF-α), on the other hand, can induce the expression of iNOS,
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which in turn to increase the production of NO.9 Increasing evidences have demonstrated that
the aberrant iNOS expression is closely associated with several malignant tumors and the
excessive NO can cause DNA damage, mutagenesis and lead to cancer progression.10,

11

Likewise, cyclooxygenase-2 (COX-2) is another pro-inflammatory enzyme that is able to
convert arachidonic acid into prostaglandins. Aberrant induction of COX-2 has been involved
in several types of cancers, by upregulating generation of prostaglandins, which promote cell
survival, angiogenesis, and metastasis.12, 13 In addition, oxidative stress occurs when the body’s
antioxidant defense system loses its capacity to response and neutralize the over generated
reactive oxygen species (ROS), which are highly active radicals able to damage vital cellular
components.14 Thus, suppression of these inflammatory molecules could be a potential strategy
for alleviating chronic inflammation and preventing the downstream chronic diseases.
Recently, numerous studies have reported the anti-inflammatory roles of dietary
polyphenols.15, 16 Dietary polyphenols are the most abundant antioxidants in our diets. The
antioxidant activity of polyphenols results from their ability donating an electron or hydrogen
atom to a wide range of reactive oxygen to neutralize free radicals, thereby attenuating
oxidative stress caused inflammation and chronic disorders.17 Apigenin (4’,5,7trihydroxyflavone, AP) (Figure 1-1), as one of the most promising polyphenols, has been well
documented as a potent anti-inflammatory agent. It was reported that apigenin significantly
decreased various cytokines (IL-1β, TNF-α, IL-6, and IL-12) in LPS-induced human
periodontal ligament cells.18 Besides, in vivo studies reported the inhibitory action of apigenin
on NO and prostaglandin E2 (PGE2) production, by inhibiting the expressions of iNOS and
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COX-2, respectively.19 Curcumin (CUR, Figure 4-1), a constituent of turmeric ginger family,
is another widely studied polyphenol due to its potential anti-inflammatory effects.20
Pretreatment with CUR was able to suppress TNF-α induced COX-2 expression, and inhibit
NF-κB activation in human colonic epithelial cells.21 In human myeloid leukemia cells, CUR
was found to inhibit the TNF-α induced nuclear translocation and DNA binding of NF-κB,
through suppression of IκBα phosphorylation and subsequent degradation.22
Single agents may not be able to inhibit the complex and multifactorial inflammation
process. On the other hand, a growing body of evidence suggests that bioactive compounds can
have different molecular targets, which may produce synergistic activities involving
antioxidation, anti-inflammation, and anti-cancer. 23 Besides, polyphenols derived from fruits
and vegetables are not under all circumstances beneficial, but in fact may cause unacceptable
toxicity in a high-dose administration.7 Hence, anti-inflammatory agents with synergistic
interactions may enhance anti-inflammatory efficacy, decrease the dosage of individual antiinflammatory agents to achieve efficacy, and reduce toxicity or side effects.23 With lower
toxicity and non-mutagenesis, AP is a promising candidate to achieve significant synergism
and simultaneously reduce the potential toxic high dosage of other agent when combined with
other polyphenols.24 In this sense, for the first time, the current study investigated the potential
synergy of physical mixtures of AP and CUR as well as their coencapsulated dispersions of
inhibiting pro-inflammatory responses in LPS-stimulated RAW 264.7 macrophage, with the
hypothesis that co-encapsulation may enhance the synergistic effects.
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4.3 Materials and methods
4.3.1 Materials
Apigenin (>98%) was purchased from Indofine Chemical Co. Inc (Hillsborough, NJ,
USA). Curcumin (95% total curcuminoid content) was purchased from Thermo Fisher
Scientific (Waltham, MA, USA). Casein sodium salt, Lipopolysaccharide (LPS; Escherichia
coli O55:B5), and 2',7'-dichlorofluorescein diacetate (DCFH-DA) were purchased from SigmaAldrich Corp. (St. Louis, MO, USA). Murine macrophage RAW 264.7 cell line was purchased
from American Type Culture Collection (Manassas, VA, USA). Growth media DMEM 1X was
purchased from Corning Inc. (Corning, NY, USA). Fetal bovine serum (FBS) was purchased
from Life Technologies (Carlsbad, CA, USA). ELISA kits (mouse TNF-α and IL-6) were
purchased from BioLegend (San Diego, CA, USA), Primary antibodies (iNOS 18985-1-AP,
COX-2 66351-1-Ig and GAPDH 60004-1-Ig) were purchased from Proteintech (Rosemont, IL,
USA). Secondary antibodies (goat anti-mouse and goat antirabbit) were purchased from LiCor Biosciences Inc. (Lincoln, NE, USA). All other chemicals were obtained from Thermo
Fisher Scientific unless otherwise stated.
4.3.2 Co-encapsulation of apigenin and curcumin
A pH-cycle method was modified and applied to co-encapsulate AP and CUR based on a
previous study.25 Sodium caseinate (NaCas) solution (2% w/v) was prepared by dissolving
desirable powder in deionized water until a complete dissolution, and stored overnight at 4 °C
to ensure complete hydration of protein molecules. AP and CUR with various mass ratios (from
4:1 to 1:4) with a constant AP concentration of 0.2 mg/mL were dissolved in the above NaCas
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solution, adjusted to pH 12.0 using 2M KOH. Mixtures were allowed to stir for 30 min at room
temperature (21 °C) before neutralizing to pH 7.0 with 1 M HCl. Dispersions were centrifuged
(Sorvall LYNX 6000 Centrifuge, Thermo Fisher Scientific, Waltham, MA, USA) at 10,000 g
for 10 min to remove unencapsulated polyphenols, leaving the supernatant as dispersions with
coencapsulated AP and CUR. The obtained precipitate was used to determine encapsulation
efficiencies by the following equation based on the absorbance at 337 nm and 419 nm for
respective apigenin and curcumin, and standard curves that were established previously.
EE % =

𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑝ℎ𝑒𝑛𝑜𝑙 (𝑚𝑔) − 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑝ℎ𝑒𝑛𝑜𝑙 𝑖𝑛 𝑝𝑟𝑒𝑐𝑖𝑝𝑖𝑡𝑎𝑡𝑒 (𝑚𝑔)
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑝ℎ𝑒𝑛𝑜𝑙 (𝑚𝑔)

× 100

4.3.3 Physicochemical characterizations of dispersions
4.3.3.1 Dynamic light scattering and zeta-potential
Particle size distributions of dispersions with AP and CUR, NaCas and NaCas after the
pH-cycle treatment under the same encapsulation conditions during 30-day ambient storage
with the addition of 0.2% sodium azide to prevent microorganisms, as well as zeta-potential
were measured using a Zetasizer Nano-ZS series instrument (Malvern Instruments Ltd.,
Worcestershire, UK).
4.3.3.2 Transmission electron microscopy (TEM)
Freshly prepared dispersions with AP and CUR at 1:1 mass ratio, NaCas, and NaCas after
the pH-cycle treatment were diluted to 0.02% w/v protein and were imaged with TEM. One
drop of each diluted sample was placed on a freshly glow-discharged carbon film on a 400mesh copper grid, stained by 1% uranyl acetate and imaged with a Zeiss Libra micrope at 200
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kV (Carl Zeiss Microscopy, Oberkochen, Germany).
4.3.4 Cytotoxicity assay
Cell viability of murine RAW 264.7 macrophages was tested to address the cytotoxicity
of AP and CUR. Stock solutions of AP and CUR were prepared by dissolving a desired amount
of compound in dimethyl sulfoxide (DMSO) to a final concentration of 10 mg/mL. RAW 264.7
macrophages were cultured at 37 °C under a humidified atmosphere of 5% CO2 in Dulbecco’s
Modified Eagle Medium (DMEM) (Corning Inc., Corning, NY, USA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (Life Tech, Carlsbad, CA, USA) and 1% v/v
penicillin/streptomycin (Life Tech, Carlsbad, CA, USA). A density of 2.5 × 104 cells/well was
used for seeding in 96-well plates to allow cells to adhere to the plate. After overnight
attachment, cells were treated with a series of concentrations of tested compounds or DMSO
(as control) in 200 μL of serum complete medium, with the presence of 1 μg/mL LPS for 24 h.
Subsequently, cells were studied with the Cell Titer 96 Aqueous One Solution Cell Proliferation
Assay (Promega, Madison, WI, USA) to measure the viability.
4.3.5 Determination of NO production
Cells were seeded as described above, and were then treated with AP only, CUR only,
physical mixtures of the two tested compounds with various mass ratios, and dispersions with
various concentrations of coencapsulated AP and CUR. Compound concentrations were below
toxicity levels, and cells were stimulated with LPS (1 μg/mL) for 24 h. Afterwards, the culture
medium were collected to measure the nitrite accumulation as an indicator of NO production
by the Griess reagent assay 26. Briefly, supernatant of each treatment (100 μL) was plated in
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microplates in triplicate, mixed with an equal volume of Griess reagent A (1% sulfanilamide in
5% phosphoric acid) and reagent B (0.1% naphthylethylenediamine dihydrochloride in water).
After 5 min incubation at room temperature, absorbance at 550 nm was recorded (Synergy H1
Hybrid Multi-Mode Reader, BioTek Instruments, Inc., Winooski, VT, USA) and the
concentration of nitrite was calculated according to a standard curve constructed with sodium
nitrite as a standard.
4.3.6 Preparation of whole cell lysates and western blot analysis
RAW 264.7 macrophage cells were seeded at a density of 2×105 in 6-well plates and
exposed to treatments of a single compound (AP or CUR), a physical mixture of AP and CUR
or a dispersion with encapsulated AP and CUR for 24 h in the presence of 1 μg/mL LPS after
overnight attachment. Whole cell lysates were collected after lysing with RIPA buffer followed
by western blot analysis. According to a previous protocol.27 Equal amounts of protein (20 μg)
were loaded into wells of a 4-20% SurePAGE, Bis-Tris gel (GenScript Biotech, Piscataway,
NJ, USA), and separated at 200V for 35 min in Tris-MOPS-SDS (GenScript Biotech,
Piscataway, NJ, USA) running buffer at ambient temperature. The gel was then transferred to
Trans-Blot Turbo PVDF membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using
Trans-Blot Turbo Transfer System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). After
blocking with 5% non-fat dry milk in tris-buffered saline containing 0.1% Tween 20 (TBST)
for 1 h at room temperature, membranes were washed three times for 5 min each with TBST.
Then, membranes were incubated with primary antibodies against iNOS and COX-2
(ProteinTech, Chicago, IL, USA) at 1:1000 dilution in 1% non-fat dry milk of TBST, and
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GAPDH at dilution of 1:5000 overnight at 4 °C. After washing three time for 10 min each with
TBST, the membrane was then incubated with anti-rabbit or anti-mouse secondary antibody at
dilution of 1:5000 for 1.5 h at room temperature. After which, the membrane was washed with
TBST three time for 10 min each, immersed with Bio-Rad ClarityTM Western ECL Substrate
(Bio-Rad Laboratories, Inc., Hercules, CA, USA), and visualized by a C-Digit blot scanner (LiCor Biosciences, Lincoln, NE, USA). The expression of proteins was calculated by quantifying
the intensity of bands using ImageJ software (NIH, Bethesda, MD, USA).
4.3.7 Measurement of pro-inflammatory cytokines
Supernatants of macrophages under various treatments collected from section 4.3.5 were
further subjected to respective enzyme-linked immunosorbent assay (ELISA) kits according to
the manufacturer’s instructions (BioLegend, San Diego, CA, USA) to quantify levels of IL-6
and TNF-α in the culture medium. Absorbance at 450 nm was recorded in a Cambrex ELX808
Microplate Reader (bioMONTR Labs, Durham, NC, USA).
4.3.8 Determination of intracellular reactive oxygen species (ROS)
4.3.8.1 Fluorescent microscopy
RAW 264.7 cells were seeded as described earlier in the cell viability section in 96-well
plates, and treated with AP or CUR individually, physical mixtures with various mass ratios of
AP and CUR, or different concentrations of coencapsulated AP and CUR for 24 h. Cells were
stimulated by 1 μg/mL LPS for the last 18 h. Afterwards, supernatants were removed before
cells were washed with 200 μL ice-cold PBS. After washing, 200 μL PBS containing 10 μM
2’,7’-dichlorofluorescein diacetate (DCFH-DA) was added into each well, followed by
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incubation at 37 °C for 30 min in dark in a 5% CO2 incubator. After removing the dye, cells
were washed with ice-cold PBS twice. Pictures indicating ROS production were acquired
immediately using a green fluorescent protein (GFP) channel with 20× magnification (model
EVOS microscope, Thermo Fisher Scientific, Waltham MA, USA).
4.3.8.2 Fluorescence spectrophotometry
Cells were treated the same way as described for fluorescent microscopy, except being
seeded in black 96-well plates. After treatments, washing with ice-cold PBS, and incubation
with PBS containing 10 µM 2’, 7’-dichlorofluorescein diacetate at 37 °C for 30 min, the
fluorescence intensity of each treatment was recorded immediately using a Synergy H1 Hybrid
Multi-Mode Reader (BioTek Instruments, Inc., Winooski, VT, USA) at excitation and emission
wavelengths of 485 nm and 528 nm, respectively.
4.3.9 Determination of synergism
The synergistic effects of AP and CUR combinations were determined by the ChouTalalay method,20, 28 by characterizing the interactions of drugs using the combination index
(CI) given as:
CI =

𝑑1
𝐷𝑥,1

+

𝑑2
𝐷𝑥,2

where d1 and d2 represent the doses of drug 1 (AP) and drug 2 (CUR) in combination; Dx,1
and Dx,2 are the corresponding doses of drug 1 (AP) and drug 2 (CUR) given individually to
produce the same effect (x). A CI of <1, =1, or >1 suggests synergism, additive or antagonism,
respectively. CI was obtained by using CompuSyn software (ComboSyn, Inc., Paramus, NJ,
USA).
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4.3.10 Statistical analysis
Data were presented as mean ± SD of at least three trials. Data were analyzed using oneway ANOVA with application of IBM SPSS Statistics version 25.0 software (SPSS Inc.,
Chicago, IL, USA) and means were considered to be significantly different at p < 0.05 as
determined by Tukey’s test for multiple comparisons.

4.4 Results and discussion
4.4.1 Physicochemical characteristics of dispersions
The optimized conditions resulted in high encapsulation efficiencies of both AP and CUR
as shown in Table 4-1. Zeta potential indicates the surface charge properties of nanoparticles.29
The magnitude of zeta-potential of native NaCas at pH 7.0 increased after the pH-cycle
treatment at the encapsulation conditions (Table 4-1), which may be due to the reduced number
of surface charges after reassembling during neutralization of acidity

25, 30

. The zeta-potential

of dispersions with various mass ratios of coencapsulated AP and CUR was similar to the pHcycle treated NaCas. In addition, zeta-potential is commonly applied to indicate colloidal
stability, with a magnitude higher than 30 mV always predicting a higher stability of
nanodispersions by electrostatic repulsion.31,

32

Therefore, the more negatively charged

nanodispersions with the elevated proportion of CUR may possess a higher stability (Table 41).
As shown in Figure 4-2A, the pH-cycle process resulted in a smaller hydrodynamic
diameter (Dh) of NaCas, which is in agreement with some previous studies.33, 34 possibly due
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to the supramolecular changes of casein particles. Encapsulating AP and CUR had insignificant
influence on Dh when compared to the pH-cycle treated NaCas.
Morphologies of NaCas before and after the pH-cycle treatment as well as the dispersion
prepared with AP and CUR at 1:1 mass ratio are presented in Figure 4-2B. Compared with the
pH-cycle treated NaCas, the unprocessed NaCas had more irregular and heterogeneous
structures. After the pH-cycle treatment, the structure became uniform and smaller, which was
in consistent with the above Dh results. Besides, co-encapsulating AP and CUR further
increased the uniformity and compactness of particles.
Co-encapsulating CUR together with AP resulted in the enhanced storage stability when
comparing to the encapsulation treatment with AP only. As shown in Figure 4-3A, the treatment
with AP only became turbid after overnight storage, while dispersions with both compounds
maintained visually clear. The stability of co-encapsulation treatments with various mass ratios
of AP and CUR was further investigated by measuring particle size distributions during 30-day
storage at room temperature (21 °C). As shown in Figure 4-3B, increasing the proportion of
CUR in the nanodispersion enhanced the storage stability of dispersions, increased from 15
days to 30 days (p > 0.05). Therefore, it is feasible to coencapsulate AP and CUR with NaCas
and obtain a stable nanodelivery system.
4.4.2 Cell viability and toxicity of apigenin and curcumin
To test the toxicity of AP and CUR, and establish nontoxic dose ranges for these two
compounds in RAW 264.7 cells, growth inhibitory activity of AP and CUR was initially
investigated for cell viability using the MTS assay. As shown in Figure 4-4A and B, AP and
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CUR at up to 12 and 6 μg/mL, respectively, did not cause a significant decrease on the viability
of RAW 264.7 cells. The calculated IC50 of AP and CUR against RAW 264.7 was 19.22 μg/mL
and 9.81 μg/mL, respectively, which indicated a much higher toxicity of CUR than AP.
Therefore, the combination of AP and CUR could decrease the dosage of CUR to potentially
minimize the toxicity and side effects.
The combination treatments with different mass ratios (from 4:1 to 1:1) of AP and CUR
at a total concentration of up to 6 ug/mL were further confirmed for insignificant effect on the
viability of RAW 264.7 cells (data not shown). Thus, nontoxic doses ranging from 0.5 ug/mL
to 6 ug/mL were selected in the following studies, to determine the possible anti-inflammatory
activities of AP and CUR, as well as their combinations in LPS-stimulated RAW 264.7 cells.
4.4.3 Synergistic inhibition of NO production
NO has been implicated as one of the key factors mediating tissue injury induced by
inflammation. Excess NO has been reported to be genotoxic by inducing DNA damage as a
reactive radical 35. Biologically produced NO is rather unstable and is rapidly oxidized to nitrite
and nitrate in water.20 As shown in Figure 4-5A, under the nontoxic dosage, AP inhibited LPSinduced NO production by 13.32, 30.23, 54.45, and 72.42% at 0.5, 1.5, 3 and 6 μg/mL,
respectively. Similarly, CUR treatments also resulted in the inhibition of NO production by
12.46, 40.32, 76.38, and 97.91% at respective concentrations of 0.5, 1.5, 3, and 6 μg/mL (Figure
4-5B).
To determine the combinational effects of AP and CUR, LPS-stimulated macrophages
were treated with a series of combinations with different mass ratios of AP and CUR under the
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established nontoxic concentrations. As shown in Figure 4-5C, combinations with an elevated
proportion of CUR possessed a stronger inhibitory activity on NO production than individual
treatments. The calculated CI (Table 4-2) decreased from 1.25 to 0.65 as the amount of CUR
increased, suggesting the transition of additive to synergistic interactions between AP and CUR.
To overcome the low solubility and bioavailability, AP and CUR were coencapsulated and
the inhibitory effects on NO production by nanodispersions with one or both compounds are
shown in Figure 4-5B. The CI was smaller than 0.8 for all co-nanoencapsulation treatments
(Table 4-2), suggesting enhanced synergistic interactions between AP and CUR at all mass
ratios after co-encapsulation. When only one compound was nanoencapsulated with NaCas,
the concentration needed to inhibit 50% NO production (IC50) was higher than the
corresponding free compound dissolved in DMSO (Table 4-2). This may result from the
reduced direct interactions between polyphenols and cells, since, after encapsulation,
polyphenol molecules bound to proteins through hydrophobic interactions and hydrogen bonds,
lower the availability to cells. The synergistic activities after co-encapsulation of AP and CUR
may result from different targets of the compounds. The enhanced synergistic interactions after
nanoencapsulation may be ascribed to the improved stability, dispersibility, and proximity of
polyphenols during cell incubation, which made it possible to better interact cells by two
compounds simultaneously.
4.4.4 Decreased expression of iNOS and COX-2
The expression level of iNOS protein was subsequently analyzed by western blot, to
obtain clear knowledge of the synergistic inhibitory mechanism of NO production by
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combinations of AP and CUR. It was hypothesized that the synergism was due to the decreased
production of the iNOS synthesis, since iNOS is responsible for sustained release of NO and
is typically synthesized in response to pro-inflammatory stimuli, which is induced in a large
variety of diseases.36
As shown in Figure 4-6A, iNOS expression significantly increased following LPS
stimulation. All treatments including individual polyphenols and physical combinations at
doses of 3 and 6 μg/mL resulted in a dose-dependent down-regulation of iNOS expression,
although lower concentrations (0.5 and 1.5 μg/mL) did not show a considerable reduction.
Treatments of 6 μg/mL AP and CUR for 24 h induced 49.7 % and 40.6% inhibition of iNOS
expression, respectively, as compared with the LPS-treated positive control cells (Figure 4-6B).
However, administrations of physical mixtures of apigenin and curcumin at different mass
ratios did not act in a synergism tendency as in the inhibition of NO production (CI ≥ 1). On
the other hand, compared to nanoencapsulation treatment with AP only or CUR only, coencapsulation treatments with a higher proportion of CUR induced a synergistic inhibition of
iNOS expression as shown in Figure 4-6C and Table 4-3, which agrees with the synergistic
reduction of NO production (Figure 4-5). These results indicate that the synergistic inhibition
of NO production by different treatments is at least partially through the suppression of iNOS
expression.
COX-2 was also determined as another important pro-inflammatory enzyme.37 As shown
in Figure 4-7A, LPS stimulated a significant increase of COX-2 expression. Under the same
treatment conditions, both free CUR and nanodispersion with CUR only at 6 μg/mL inhibited
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almost 100% expression of COX-2 (Figure 4-7B, C). The inhibitory activity of AP and
encapsulated AP was not as strong as CUR, however, with respective reduction of 64% and
74.7% at 6 μg/mL (Figure 4-7B, C). Due to the strong suppression of CUR, none of the
combinations acted in a synergistic behavior, although all of them possessed a dose-dependent
inhibitory manner and resulted in significant reduction of COX-2 level.
The exact cellular mechanisms of AP and CUR as well as their combinations for downregulating iNOS and COX-2 in RAW 264.7 cells remain to be understood. They may have
effects on upstream of signal transduction involving activation or translocation of transcription
factors such as nuclear factor kappa B (NF-kB), or they may affect the translational level of
enzyme expression.38 The differences of synergistic inhibitory activities noted in the iNOS and
COX-2 expressions may be due to the degree of dependence of enzyme promoters or
transcription factors on polyphenols and their combinations. Nevertheless, further studies are
needed to clarify these points.
4.4.5 Synergistic suppression of IL-6 and TNF-α
IL-6 and TNF-α were quantified as they are two important pro-inflammatory cytokines.
In negative control cells, both IL-6 and TNF-α were generated in vanishingly small quantities
but produced in a large increasing amount when stimulated with LPS. As shown in Figure 4-8,
all treatments showed a dose-dependent manner to inhibit the production of IL-6. AP
significantly suppressed IL-6 production by 28.04%, 50.98%, and 81.32% at 1.5, 3, and 6
μg/mL, respectively. Compared to AP, free CUR induced a lower extent of inhibition at low
concentrations but a larger degree of reduction in high concentration, with 13.88%, 56.07%
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and 90.36% inhibition at respective concentrations of 1.5, 3, and 6 μg/mL (Figure 4-8A).
Similar to the NO production, combinations of free AP and CUR with increased concentrations
of CUR resulted in synergistic inhibitory effects on IL-6 production, and co-encapsulation
enhanced the synergism with CI values smaller than 1 (Table 4-4).
The studied treatments affected the production of TNF-α with a much lower inhibition
extent. As shown in Figure 4-9A, at up to 6μg/mL, AP and CUR induced up to 30.63% and
57.32% inhibition, respectively. These results indicate that separate mechanisms may possibly
exist in the production of TNF‑α and IL‑6 in LPS‑stimulated macrophages, which are
differentially influenced by polyphenols. Several studies have demonstrated that polyphenols
differentially modulate the expression of cytokines. It was reported that quercetin and galangin
inhibited the production of IL-6, but not TNF-α.39 It should be noted, however, that similar
synergistic interactions were observed in the free polyphenol mixtures with a higher proportion
of CUR (Table 4-5) and co-encapsulation enhanced synergism (Figure 4-9B), showing a
significantly higher reduction of TNF-α production compared with nanodispersions with only
one polyphenol at 6 μg/mL.
4.4.6 Synergistic inhibition of ROS production
In the current study, the levels of ROS were evaluated using fluorescence microscopy and
spectrophotometry in the absence or presence of polyphenols and their combinations in
RAW264.7 cells. As shown in Figure 4-10, without LPS treatment, ROS was not detectable but
increased significantly following LPS treatment as strong fluorescence signals were observed.
Compared with the LPS-treated control cells, the fluorescence intensity decreased dramatically
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in the presence of 6 μg/mL of polyphenols in all different treatments, suggesting a potent
inhibitory activity of the studied compounds and the combinations.
The suppressant effects of these treatments were further confirmed by quantitative
fluorescence spectrophotometry. As shown in Figure 4-11, all polyphenol treatments reduced
the production of ROS triggered by LPS. Compared to the positive cells treated with LPS only,
free AP at 1.5, 3, and 6 μg/mL suppressed 13.55%, 24.41% and 43.18% of ROS production,
respectively. CUR exerted a weaker inhibitory activity at lower concentrations as 1.5 and 3
μg/mL administrations resulted in 8.69% and 18.84% reduction of ROS, respectively, while a
stronger suppression of 75.96% was observed at 6 μg/mL. Besides, the calculated CI values
(Table 4-6) confirmed the synergistic interactions between AP and CUR, with an enhanced
synergism after co-encapsulation. Therefore, inhibiting ROS production is one of the possible
mechanisms that contribute to the anti-inflammatory activities of AP and CUR as well as their
combinations.

4.5 Conclusions
It was firstly to found that co-encapsulating curcumin together with apigenin using NaCas
gave rise to the enhanced storage stability with respect to the nanodispersion encapsulated with
apigenin only. With the increased proportion of curcumin, the nanodispersions coencapsulated
with apigenin and curcumin resulted in a longer ambient storage period (21 °C). Besides, under
non-toxic concentrations, combing apigenin and curcumin with higher mass ratios of curcumin
in the simple mixtures synergistically diminished NO production, suppressed iNOS expression,
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decreased pro-inflammatory cytokines (IL-6 and TNF-α), and reduced ROS production in LPSinduced RAW 264.7 macrophages (CI < 1). Co-encapsulation of apigenin and curcumin with
NaCas resulted in the enhanced anti-inflammatory activities. These results provide new
insights on synergistic interactions between dietary bioactive compounds. However, molecular
mechanisms that are responsible for the enhanced synergistic interactions after coencapsulation as well as those upstream signaling pathways that contribute to the above
inflammatory mediators remains further elaboration.
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Appendix
Table 4-1. Encapsulation efficiency and zeta-potential of dispersions after the pH-cycle
treatment of 2% w/v sodium caseinate (NaCas) and 0.2 mg/mL polyphenols or with different
mass ratios of apigenin (AP) : curcumin (CUR) at a constant AP concentration of 0.2 mg/mL.
AP:CUR
1:0
0:1
4:1
3:1
2:1
1:1
1:2
1:3
1:4

Encapsulation Efficiency
EE% of AP
EE% of CUR
b,c
96.17% ± 0.008
96.70% ± 0.004 a,b
96.63% ± 0.001 a,b,c 93.26% ± 0.010 d
95.99% ± 0.001 c
94.11% ± 0.008 c, d
96.41% ± 0.002 b,c 95.70% ± 0.002 b, c
96.26% ± 0.003 b,c 95.81% ± 0.019 b, c
97.46% ± 0.002 a
98.47% ± 0.001 a
97.09% ± 0.001 a,b
98.73% ± 0.001 a
97.00% ± 0.004 a,b
98.32% ± 0.008 a
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Zeta-potential
Sample
Zeta-potential (mV)
NaCas
-21.10 ± 1.44 c
pH-NaCas
-31.40 ± 1.73 b
AP:C=1:1
-33.43 ± 1.00 a, b
AP:C=1:2
-33.10 ± 0.70 a, b
AP:C=1:3
-32.03 ± 0.84 b
AP:C=1:4
-35.17 ± 0.42 a
Numbers are mean ± standard deviations
(n = 3). Different superscript letters
indicate significant differences (p < 0.05).

Table 4-2. Concentrations of free or encapsulated (En) apigenin (AP) and curcumin (CUR) to
inhibit 50% of NO production (IC50) and combination index (CI) calculated for combinations
with various mass ratios of free or co-encapsulated (CoEn) AP and CUR on NO production in
LPS-stimulated RAW 264.7 cells.
Free-AP
Free-CUR
Free-AP:CUR=4:1
Free-AP:CUR=3:1
Free-AP:CUR=2:1
Free-AP:CUR=1:1
Free-AP:CUR=1:2
Free-AP:CUR=1:3
Free-AP:CUR=1:4

IC50 (μg/mL)
2.41
1.43
CI
1.246
1.099
1.125
1.128
0.957
0.652
0.789

En-AP
En-CUR
CoEn-AP:CUR=4:1
CoEn-AP:CUR=3:1
CoEn-AP:CUR=2:1
CoEn-AP:CUR=1:1
CoEn-AP:CUR=1:2
CoEn-AP:CUR=1:3
CoEn-AP:CUR=1:4
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IC50 (μg/mL)
4.40
3.51
CI
0.629
0.703
0.474
0.582
0.543
0.683
0.553

Table 4-3. Combination index (CI) calculated for combination effects of coencapsulated (CoEn)
apigenin (AP) and curcumin (CUR) at different mass ratios on expression of iNOS triggered
by LPS activation.
CoEn-AP:CUR=4:1
CoEn-AP:CUR=3:1
CoEn-AP:CUR=2:1
CoEn-AP:CUR=1:1

CI
1.405
1.472
0.870
0.932

CoEn-AP:CUR=1:2
CoEn-AP:CUR=1:3
CoEn-AP:CUR=1:4
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CI
0.777
0.609
0.457

Table 4-4. Concentrations of free or encapsulated (En) apigenin (AP) and curcumin (CUR) to
inhibit 50% of IL-6 level (IC50) and combination index (CI) calculated for combinations with
various mass ratios of free or co-encapsulated (CoEn) AP and CUR on IL-6 production induced
by LPS stimulation.
Free-AP
Free-CUR
Free-AP:CUR=4:1
Free-AP:CUR=3:1
Free-AP:CUR=2:1
Free-AP:CUR=1:1
Free-AP:CUR=1:2
Free-AP:CUR=1:3
Free-AP:CUR=1:4

IC50 (μg/mL)
2.69
2.78
CI
1.349
1.310
1.244
1.243
0.860
0.699
0.725

En-AP
En-CUR
CoEn-AP:CUR=4:1
CoEn-AP:CUR=3:1
CoEn-AP:CUR=2:1
CoEn-AP:CUR=1:1
CoEn-AP:CUR=1:2
CoEn-AP:CUR=1:3
CoEn-AP:CUR=1:4
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IC50 (μg/mL)
5.36
5.83
CI
0.519
0.721
0.664
0.675
0.647
0.866
0.568

Table 4-5. Concentrations of free apigenin (AP) and curcumin (CUR) to inhibit 50% of TNFα level (IC50) and combination index (CI) calculated for combinations with various mass ratios
of free AP and CUR on TNF-α level induced by LPS stimulation.
Free-AP
Free-AP:CUR=4:1
Free-AP:CUR=3:1
Free-AP:CUR=2:1
Free-AP:CUR=1:1

IC50 (μg/mL)
12.32
CI
1.500
1.486
1.162
1.381

Free-CUR
Free-AP:CUR=1:2
Free-AP:CUR=1:3
Free-AP:CUR=1:4
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IC50 (μg/mL)
5.45
CI
0.978
0.563
0.732

Table 4-6. Concentrations of free or encapsulated (En) apigenin (AP) and curcumin (CUR) to
inhibit 50% of ROS production (IC50) and combination index (CI) calculated for combinations
with various mass ratios of free or co-encapsulated (CoEn) AP and CUR on ROS production
in LPS-induced RAW 264.7 cells.
Free-AP
Free-CUR
Free-AP:CUR=4:1
Free-AP:CUR=3:1
Free-AP:CUR=2:1
Free-AP:CUR=1:1
Free-AP:CUR=1:2
Free-AP:CUR=1:3
Free-AP:CUR=1:4

IC50 (μg/mL)
7.79
4.26
CI
0.878
0.816
0.832
0.875
0.794
0.744
0.727

En-AP
En-CUR
CoEn-AP:CUR=4:1
CoEn-AP:CUR=3:1
CoEn-AP:CUR=2:1
CoEn-AP:CUR=1:1
CoEn-AP:CUR=1:2
CoEn-AP:CUR=1:3
CoEn-AP:CUR=1:4
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IC50 (μg/mL)
11.48
4.22
CI
0.620
0.665
0.653
0.720
0.652
0.750
0.672

Figure 4-1. Molecular structure of
methoxyphenyl)hepta-1,6-diene-3,5-dione.

curcumin,
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(1E,6E)-1,7-Bis(4-hydroxy-3-

Figure 4-2. (A) Hydrodynamic diameter distributions of pH 7.0 dispersions of sodium
caseinate (NaCas), pH-cycle treated NaCas (pH-NaCas) and coencapsulated apigenin (AP) and
curcumin (CUR) at different mass ratios; (B) TEM images of (a) NaCas; (b) pH-NaCas, and
(c) dispersion with AP and CUR at 1:1 mass ratio.
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Figure 4-3. (A) Visual appearance of nanodispersions prepared in 2% w/v NaCas and constant
0.2 mg/mL apigenin (AP) at mass ratio of AP:curcumin (CUR) (1) 1:1, (2) 1:2, (3) 1:3, (4) 1:4,
and (5) 1:0; (B) Particle size distributions of the dispersions prepared with AP and CUR at mass
ratios of (a) 1:1, (b) 1:2, (c) 1:3, and (d) 1:4 during ambient storage (21 °C) for up to 30 days.

172

Figure 4-4. Effects of 0-30 μg/mL apigenin (A) and 0-15 μg/mL curcumin (B) on viability of
lipopolysaccharide (LPS+) activated macrophages. Error bars are standard deviations (n ≥ 3).
Different letters above columns indicate significant differences (p < 0.05).
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Figure 4-5. Percentage of inhibition on NO production in LPS-induced RAW 264.7 cells by
free (A) or encapsulated (B) apigenin (AP) or curcumin (CUR); free AP and CUR at different
mass ratios (C); and AP and CUR co-encapsulated at different mass ratios (D). Error bars are
standard deviations (n ≥ 3). Different letters above columns in A and B indicate significant
differences (p < 0.05).
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Figure 4-6. Western blot analysis of iNOS expression in LPS-induced RAW 264.7 cells as
inhibited by 0-6 μg/mL free or encapsulated (En) apigenin (AP) and curcumin (CUR) at mass
ratios from 1:0 to 0:1: images (A) and relative expression (B, free; C, En). GAPDH represents
the housekeeping protein. The first “0 μg/mL” represents the negative control without LPS and
polyphenols. The second “0 μg/mL” represents the positive control with LPS but without
polyphenols. Relative expression of iNOS protein was calculated compared to the positive
control cells. Error bars are standard deviations (n = 3).
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Figure 4-7. Western blot analysis of COX-2 expression in LPS-induced RAW 264.7 cells as
inhibited by 0-6 μg/mL free or encapsulated (En) apigenin (AP) and curcumin (CUR) at mass
ratios from 1:0 to 0:1: images (A) and relative expression (B, free; C, En). GAPDH represents
the housekeeping protein. The first “0 μg/mL” represents the negative control without LPS and
polyphenols. The second “0 μg/mL” represents the positive control with LPS but without
polyphenols. Relative expression of COX-2 protein was calculated compared to the positive
control cells. Error bars are standard deviations (n = 3).
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Figure 4-8. IL-6 production in RAW 264.7 cells stimulated with 1μg/mL LPS for 24 h as
inhibited by 1.5-6.0 μg/mL free (A) or encapsulated (B) apigenin (AP) and curcumin (CUR) at
different mass ratios. The inhibition percentage was calculated with respect to the LPS-treated
positive control. Error bars are standard deviations (n = 3).
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Figure 4-9. TNF-α production in 1μg/mL LPS-induced RAW 264.7 cells for 24 h as inhibited
by 1.5-6.0 μg/mL free (A) or 6.0 μg/mL encapsulated (B) apigenin (AP) and curcumin (CUR)
at different mass ratios. The inhibition percentage was calculated with respect to the LPStreated positive control. Error bars are standard deviations (n = 3). Different letters above
columns in B indicate significant difference (p < 0.05).
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Figure 4-10. Fluorescence microscopy analysis of intracellular reactive oxygen species (ROS)
production as inhibited by 6 μg/mL free (A) and encapsulated (B) apigenin and curcumin at
mass ratios of (3)1:0, (4) 0:1, (5) 4:1, (6) 3:1, (7) 2:1, (8) 1:1, (9) 1:2, (10) 1:3, and (11) 1:4.
Cells were treated for 24 h and were activated by 1 μg/mL LPS in the last 18 h. Figure 1 shows
the negative control without LPS and polyphenols. Figure 2 shows the positive control with
LPS but without polyphenols. Pictures were taken at 20× magnification after incubation with
10 μM of 2’,7’-dichlorofluorescein diacetate.
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Figure 4-11. Production of reactive oxygen species (ROS) as inhibited by 1.5-6.0 μg/mL free
(A) or encapsulated (B) apigenin (AP) and curcumin (CUR) at different mass ratios
investigated by fluorescence spectrophotometry at 485 nm/528 nm. Cells were treated for 24 h
and were activated by 1 μg/mL LPS in the last 18 h. Inhibition percentage was calculated based
on fluorescence intensity at 485 nm/528 nm with respect to the positive control. Error bars are
standard deviations (n = 3).
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Chapter 5. Concluding remarks and future work
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5.1 Conclusions
Colorectal cancer (CRC) continues to be a major health concern worldwide, accounting
for the second leading cause of cancer-related death. The poor lifestyle and unhealthy diets are
largely responsible for the increased incidence. Chronic inflammation is another great threat to
public health since it has long been recognized as a risk factor on the progression of various
human cancers. Due to the side effects of current treatments, many efforts have been focused
on natural polyphenols as potential alternatives to intervene the above threatening health
problems.
Apigenin is one of the most promising polyphenols with low toxicity. However, the poor
water solubility of apigenin is an important obstacle to achieve higher efficacy as a therapeutic
agent. The aim of this dissertation was to fabricate a low-cost, organic solvent-free and food
biopolymer-based nanodelivery system, and evaluate the anti-colorectal cancer fate of the
nanodelivered apigenin both in vitro and in vivo, as well as the anti-inflammatory activities in
the LPS-activated macrophages, with a focus to enhance synergistic effects of co-encapsulated
apigenin and curcumin.
In chapter 2, a pH-cycle method was effectively applied to encapsulate apigenin in whey
protein isolate, to achieve high encapsulation efficiency, loading capacity and good storage
stability. The improved solubility, stability and dispersibility of apigenin
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nanoencapsulation significantly enhanced the cellular uptake of apigenin in human colon
cancer cells (HCT-116 and HT-29). Both free and nanoencapsulated apigenin possessed
promising anti-proliferative activity against HCT-116 and HT-29, which was correlated to the
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induction of cell apoptosis. These results suggest the potential of the nanodelivered apigenin
in the development of functional beverages for disease prevention.
In Chapter 3, the in vivo efficacy of apigenin encapsulated in WPI was evaluated. Oral
bioavailability of apigenin in the mice serum and colon mucosa was significantly enhanced by
nanoencapsulation to 1.39 times and 1.41 folds that of free apigenin, respectively. In vivo anticancer activity investigated in ApcMin/+ mice, by evaluating tumorigenesis, tissue apoptosis,
tumor markers expression and levels of pro-inflammatory cytokines, however, was not
significantly different among different treatment groups. Both free and encapsulated apigenin
did not positively suppress colon carcinogenesis in vivo in the current animal model. More
comprehensive and extensive studies need to be done to address the potential in vivo anticancer
activity of nanoencapsulated apigenin.
In Chapter 4, the synergistic anti-inflammatory activity in LPS-stimulated RAW 264.7
cells was investigated for apigenin and curcumin, in simple mixture and coencapsulated forms.
Results showed that, under non-toxic concentrations, the simple mixtures with a higher
proportion of curcumin showed a greater extent of synergism inhibiting NO production,
suppressing iNOS enzyme expression, decreasing pro-inflammatory cytokines (IL-6 and TNFα), and reducing ROS level. These synergistic anti-inflammatory effects of apigenin and
curcumin were found to be enhanced after co-encapsulation.
Overall, this dissertation research resulted in a novel, scalable and food grade
nanodelivery system for apigenin. The nanodelivered apigenin showed the anticancer and antiinflammatory activities. The understanding of the in vivo efficacy of nanoencapsulated
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apigenin and the enhanced synergistic interactions of coencapsulated apigenin and curcumin
may provide multi-perspectives to develop functional foods incorporated with lipophilic
phytochemicals for disease intervention.

5.2 Future work
Results in the current dissertation have demonstrated that nanoencapsulation using dairy
proteins enhanced bioavailability of apigenin in the colon mucosa of apigenin. However, the
nanoencapsulated apigenin did not significantly affect colon carcinogenesis in vivo. In addition
to further studies that involve different dosages and mouse models to assess the potential in
vivo anticancer efficacy of nanodelivered apigenin, nanoparticles can be further modified to
improve their stability and enhance the anticancer effects of encapsulated compounds in vivo.
As found in chapter 2, WPI was easily hydrolyzed by enzymes in gastrointestinal digestions,
and covering another layer of indigestible polymer can be studied to result in a slower release
of apigenin and thereby may lower the elimination rate and enhance the bioavailability in vivo.
For instance, as a positive charged biocompatible polysaccharide, chitosan not only can
improve the stability of nanoparticles, but also has been used as an absorption enhancer as the
outside layer due to its mucous adhesiveness, and thus enhance the bioavailability of
polyphenols.1, 2 Besides, since apigenin can accumulate in the colon mucosa, it would be of
great importance to incorporate target ligands such as antibodies, small peptides and receptor
binding agents on the surface of nanoparticles to increase the target specificity for colon cancer
delivery meanwhile decrease the potential toxicity and adverse effects to normal cells.3 Other
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studies such as analyzing the metabolites of apigenin, fluorescent labeling4 of nanoparticles to
investigate the bio-distribution, absorption, and metabolism of apigenin, may help to explain
the mechanisms and in vivo anticancer efficacy of apigenin.
On the other hand, it has been reported that combinations of two or more phytochemicals
bring about changes in the ultimate biological effects, such as synergistic anti-oxidant, anticancer and anti-inflammatory activities. Compared with free polyphenols, the enhanced
synergistic anti-inflammatory activities were observed after co-encapsulating apigenin and
curcumin. Interestingly, the storage stability of apigenin in dispersion was also enhanced by
co-encapsulating with curcumin. Therefore, apart from the biological activities, further studies
such as molecular modelling approaches that investigate the molecular and atomic level
mechanisms of such interactions may help to provide valuable insights to develop
coencapsulated systems to achieve synergistic biological activities.
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